

ATTORNEYS DOCKET NUMBER  
VOS 2**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

09/857408

INTERNATIONAL APPLICATION NO.  
PCT/NL99/00743INTERNATIONAL FILING DATE  
03 December 1999PRIORITY CLAIMED  
04 December 1998

## TITLE OF INVENTION

ARRAY AND METHOD FOR ANALYSING NUCLEIC ACID SEQUENCES

## APPLICANT(S) FOR DO/EO/US


Petrus Antonius Josephina VOS et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not transmitted by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - b. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
  - ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information.
  - ☒ Courtesy copy of the International Application as filed.
  - ☒ Courtesy copy of the first page of the International Publication (WO00/34518).
  - ☒ Courtesy copy of the International Preliminary Examination Report. There were no annexes.
  - ☒ Formal drawings, 10 sheets, Figures 1A-12.
  - ☒ Courtesy Copy of the International Search Report.
  - ☒ Application Data Sheet
  - ☒ The application is (or will be) assigned to: Keygene N.V., whose address is P.O. Box 216, NL-6700 AE WAGENINGEN, the Netherlands.

U.S. APPLICATION NO (If known, see 37 CFR 1.5)	International Application No <b>PCT/NL99/00743</b>	Attorney's Docket No <b>VOS 2</b>
09/857408		
17. [x] The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00		CALCULATIONS PTO USE ONLY
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than [ ] 20 [X] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00
Claims as Originally Presented	Number Filed	Number Extra
Total Claims	31 - 20	11
Independent Claims	03 - 3	
Multiple Dependent Claims (if applicable)		+ \$270.00
TOTAL OF ABOVE CALCULATIONS =		\$ 1,458.00
Claims After Post Filing Prel. Amend	Number Filed	Number Extra
Total Claims	- 20	
Independent Claims	- 3	
TOTAL OF ABOVE CALCULATIONS =		\$ 1,458.00
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.		\$
SUBTOTAL =		\$ 1,458.00
Processing fee of \$130.00 for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(d)).		\$
TOTAL NATIONAL FEE =		\$ 1,458.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$
TOTAL FEES ENCLOSED =		\$ 1,458.00
Amount to be:		\$
refunded		\$
charged		\$
a. [ ] A check in the amount of \$_____ to cover the above fees is enclosed. b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$ 1,458.00, is attached. c. [ ] Please charge my Deposit Account No. <b>02-4035</b> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. d. [XX] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <b>02-4035</b> . A duplicate copy of this sheet is enclosed.		
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>		
SEND ALL CORRESPONDENCE TO:  <b>BROWDY AND NEIMARK, P.L.L.C.</b> <b>624 NINTH STREET, N.W., SUITE 300</b> <b>WASHINGTON, D.C. 20001</b> <b>TEL: (202) 628-5197</b> <b>FAX: (202) 737-3528</b> <b>Date of this submission: June 4, 2001</b>		
Form PTO-1390 (as slightly revised by Browdy and Neimark)		SIGNATURE  Roger L. Browdy NAME 25,618 REGISTRATION NUMBER

#7/c  
RECEIVED 10 SEP 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ) Box PCT  
VOS et al ) Examiner:  
Appln. No.: 09/857,408 )  
IA No.: PCT/NL99/00743 ) Washington, D.C.  
IA Filed: December 3, 1999 ) September 10, 2001  
For: ARRAY AND METHOD FOR ) Atty.Docket: VOS=2  
ANALYZING NUCLEIC ACID )  
SEQUENCES )

RESPONSE TO NOTIFICATION TO COMPLY WITH  
SEQUENCE LISTING REQUIREMENTS

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notification to Comply dated July 10, 2001, and prior to the examination of the above-described application, please amend the present application as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 27, line 18, with the following rewritten paragraph:

--The paragraph beginning at line 18 of page 27 has been amended as follows:

Each primer of an APC can be represented schematically as:

5'- AAAAAAAAAAAAAA - RRR - NNN -3' (SEQ ID NO:39)

in which N is a nucleotide corresponding to the adapter sequence, R is a nucleotide corresponding to the restriction sequence, N is a selective nucleotide (the number of nucleotides

09857408-091001

A, R, and N may vary and may be different than shown); or alternatively as

[adapter] - [restr. enzyme] - NNN

in which [adapter] is the adapter sequence, [restr. enzyme] is the restriction sequence, and N is a selective nucleotide.--

IN THE SEQUENCE LISTING

Please enter the attached Sequence Listing, numbered as pages 1-9.

09857408-000001

**REMARKS**

Applicants have added into the present specification a new paper copy Sequence Listing section according to 37 C.F.R. §1.821(c) as new pages 1-9. Furthermore, attached hereto is a 3 1/2" disk containing the "Sequence Listing" in computer readable form in accordance with 37 C.F.R. §1.821(e).

Applicants have amended the specification to insert SEQ ID NO:39, as supported in the present specification.

The following statement is provided to meet the requirements of 37 C.F.R. §1.821(f) and 1.821(g).

I hereby state, in accordance with 37 C.F.R. §1.821(f), that the content of the attached paper and computer readable copies of the sequence listing are believed to be the same.

I hereby also state, in accordance with 37 C.F.R. §1.821(g), that the submission is not believed to include new matter.

Under U.S. rules, each sequence must be classified in <213> as an "Artificial Sequence", a sequence of "Unknown" origin, or a sequence originating in a particular organism, identified by its scientific name.

Neither the rules nor the MPEP clarify the nature of the relationship which must exist between a listed sequence and an organism for that organism to be identified as the origin of the sequence under <213>.

Hence, counsel may choose to identify a listed sequence as associated with a particular organism even though

that sequence does not occur in nature by itself in that organism (it may be, e.g., an epitopic fragment of a naturally occurring protein, or a cDNA of a naturally occurring mRNA, or even a substitution mutant of a naturally occurring sequence). Hence, the identification of an organism in <213> should not be construed as an admission that the sequence *per se* occurs in nature in said organism.

Similarly, designation of a sequence as "artificial" should not be construed as a representation that the sequence has no association with any organism. For example, a primer or probe may be designated as "artificial" even though it is necessarily complementary to some target sequence, which may occur in nature. Or an "artificial" sequence may be a substitution mutant of a natural sequence, or a chimera of two or more natural sequences, or a cDNA (i.e., intron-free sequence) corresponding to an intron-containing gene, or otherwise a fragment of a natural sequence.

The Examiner should be able to judge the relationship of the enumerated sequences to natural sequences by giving full consideration to the specification, the art cited therein, any further art cited in an IDS, and the results of his or her sequence search against a database containing known natural sequences.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Applicants submit that the present application contains patentable subject matter and therefore urge the examiner to pass the case to issuance.

If the examiner has any questions or comments concerning the above described application, the examiner is urged to contact the undersigned at the phone number below.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By 

ANNE M. KORNBau  
Registration No. 25,884

AMK:al  
624 Ninth Street, N.W.  
Washington, D.C. 20001  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528

F:\N\nde\Vos 2\PTO\RESPONSE TO NOTICE TO COMPLY.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

The paragraph beginning at line 18 of page 27 has been amended as follows:

Each primer of an APC can be represented schematically as:

5'- AAAAAAAAAAAAAA - RRR - NNN -3' (SEQ ID NO:39)

in which N is a nucleotide corresponding to the adapter sequence, R is a nucleotide corresponding to the restriction sequence, N is a selective nucleotide (the number of nucleotides A, R, and N may vary and may be different than shown); or alternatively as

[adapter] - [restr.enzyme] - NNN

in which [adapter] is the adapter sequence, [restr.enzyme] is the restriction sequence, and N is a selective nucleotide.



## SEQUENCE LISTING

<110> VOS, Josephina  
 VAN EIJK, Michael J. T.  
 HOGERS, Rene C.J.  
 HEIJNEN, Leo

<120> ARRAY AND METHOD FOR ANALYZING NUCLEIC ACID SEQUENCES

<130> VOS=2

<140> US 09/857,408  
 <141> 2001-06-04

<150> PCT/NL99/00743  
 <151> 1999-12-03

<150> EP 98204114.7  
 <151> 1998-12-04

<160> 39

<170> PatentIn Ver. 2.1

<210> 1  
 <211> 43  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:primer 98L19

<400> 1  
 agcggataac aatttcacac aggatagact gcgtacgaat tca 43

<210> 2  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:E01

<400> 2  
 gactgcgtac caattca 17

<210> 3  
 <211> 41  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:primer 98L20

<400> 3  
 cgccagggtt ttcccagtca cgacgatgag tcttgattaa c 41

<220>  
<223> Description of Artificial Sequence: M02

```
<210> 5
<211> 43
<212> DNA
<213> Artificial Sequence
```

<400> 5  
agcggataac aatttcacac aggatagact gcgtacctgc aqa 43

```
<210> 6
<211> 17
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence: P01

<400> 6  
gactgcgtac atgcaga 17

```
<210> 7
<211> 17
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence:PS01

```
<400> 7
gactgcgtac ctgcaga
```

```
<210> 8
<211> 40
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence:primer 98L89

<400> 8  
agcggataac aatttcacac aggatagact gcgtacctgc 40

<210> 9  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:P00

<400> 9  
gactgcgtac atgcag 16

<210> 10  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:description of  
Artificial Sequence:primer 98L58

<400> 10  
ggaacacagct atgaccatga ttac 24

<210> 11  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:primer 89L55

<400> 11  
gattgtactg agagtgacc ttaac 25

<210> 12  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:primer E11

<400> 12  
gactgcgtac caattcaa 18

<210> 13  
<211> 19  
<212> DNA  
<213> Artificial Sequence

```

<220>
<223> Description of Artificial Sequence:primer M47

<400> 13
gatgagtcct gagtaacaa

<210> 14
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer M49

<400> 14
gatgagtcct gagtaacag

<210> 15
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer M50

<400> 15
gatgagtcct gagtaacat

<210> 16
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 16
agcggataac aatttcacac aggatagact ggcgtacgaat tca

<210> 17
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 17
cgccaggggtt ttcccagtcga cgaacgatgag tcctgattaa c

<210> 18
<211> 18
<212> DNA

```

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer M15

<400> 18

gatgagtcct gagtaaca

18

<210> 19

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer E33

<400> 19

gactgcgtag caattcaag

19

<210> 20

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer M50

<400> 20

gatgagtcct gagtaacat

19

<210> 21

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer E11

<400> 21

gactgcgtag caattcaa

18

<210> 22

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer M62

<400> 22

gatgagtcct gagtaactt

19

<210> 23

<211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:primer E11  
  
 <400> 23  
 gactgcgtag caattcaa 18  
  
 <210> 24  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:primer M62  
  
 <400> 24  
 gatgagtcct gagtaactt 19  
  
 <210> 25  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:primer E01  
  
 <400> 25  
 gactgcgtag caattca 17  
  
 <210> 26  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:primer M16  
  
 <400> 26  
 gatgagtcct gagtaacc 18  
  
 <210> 27  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:primer M17  
  
 <400> 27  
 gatgagtcct gagtaacg 18

<210> 28  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:primer E12

<400> 28  
 gactgcgtac caattcac 18

<210> 29  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:oligonucleotide

<400> 29  
 gtcctcatca agtaatagtc ag 22

<210> 30  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:oligonucleotide

<400> 30  
 ctgactatta cttgatgagg ac 22

<210> 31  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:oligonucleotide

<400> 31  
 cttgatcagg aagactttac tc 22

<210> 32  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:oligonucleotide

<400> 32

gagtaaagtc ttctgatca ag

22

<210> 33

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 33

cttcatttat cctcgatata tg

22

<210> 34

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 34

catgtatcga ggataaatga ag

22

<210> 35

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 35

ggcaatgcaa gtagatactt c

21

<210> 36

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 36

gaagtatcta cttgcattgc c

21

<210> 37

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide



<400> 37  
cagtgtgcta gttgattcca g 21

<210> 38  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 38  
ctggaatcaa ctgacacact g 21

<210> 39  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:synthetic

<220>  
<221> misc\_feature  
<222> (14)..(16)  
<223> "r" is a nucleotide corresponding to the restriction  
sequence

<220>  
<221> misc\_feature  
<222> (17)..(19)  
<223> "n" is a selective nucleotide

<400> 39  
aaaaaaaaaa aaarrrrnnn 19

**QUESTIONS**

ATTY.'S DOCKET: VOS2

In re Application of:	)	Art Unit:
	)	
Petrus A.J. VOS, et al.	)	Examiner:
	)	
I.A. No.: PCT/NL99/00743	)	
	)	
I.A. Filed: 03 December 1999	)	
	)	
Serial No.: 09/857,408	)	Confirmation No.
(Nationalized)	)	
	)	
Filed: June 4, 2001	)	Washington D.C.
	)	
For: ARRAY AND METHOD FOR	)	September 10, 2001
ANALYSING NUCLEIC	)	
ACID SEQUENCES	)	

## SECOND PRELIMINARY AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Prior to examination of the above-identified application, please enter the following Preliminary Amendment:

## IN THE CLAIMS

Please amend claim 2 as follows:

2. (Amended) The array according to claim 1, which comprises at least 10 different nucleic acid sequences bound to the carrier.

Please amend claim 3 as follows:

3. (Amended) The array according to claim 1, in which each of the different nucleic acid sequences is bound to the carrier in such a way that it is attached to, and corresponds with, a distinct part of the carrier, so as to form an independently detectable area of the array.

In re I.A. No.: PCT/NL99/00743

In re Serial No.: 09/857,408 (Nationalized)

Please amend claim 4 as follows:

4. (Amended) The array according to claim 1 in which the density of the different nucleic acid sequences bound to the carrier is in the range of 1-100,00 different sequences/cm<sup>2</sup>.

Please amend claim 5 as follows:

5. (Amended) The array according to claim 1 in which restriction fragment sequences present in the nucleic acid sequences bound to the carrier have a size of 10 to 1200 nucleotides, and optionally include partial nucleotide sequences obtained by restricting the restriction fragments generated from the starting genomic DNA and/or cDNA with one or more further restriction enzymes, and/or *de novo* synthesized oligonucleotides based thereon and/or derived thereof.

Please amend claim 6 as follows:

6. (Amended) The array according to claim 1 in which the restriction fragments have been derived from genomic DNA, and in which at least 50% of the nucleic acid sequences bound to the carrier comprise the sequence of a restriction fragment that corresponds to an AFLP-marker.

In re I.A. No.: PCT/NL99/00743  
In re Serial No.: 09/857,408 (Nationalized)

Please amend claim 7 as follows:

7. (Amended) The array according to claim 6, comprising a plurality of AFLP-markers taken from a single individual or from a group of related individuals.

Please amend claim 8 as follows:

8. (Amended) The array according to claim 6, comprising several sets of AFLP-markers, in which each set comprises one or more markers taken from a single individual, wherein said sets of one or more markers have been taken from individuals belonging to a group of related individuals.

Please amend claim 9 as follows:

9. (Amended) The array according to claim 6 in which the AFLP-markers have been taken from individuals belonging to the same species of plant, animal or microorganism.

Please amend claim 10 as follows:

10. (Amended) The array according to claim 7 in which the AFLP-markers have been taken from, or are representative for, different subspecies, varieties, cultivars or races of the same species.

In re I.A. No.: PCT/NL99/00743  
In re Serial No.: 09/857,408 (Nationalized)

Please amend claim 11 as follows:

11. (Amended) The array according to claim 9, in which the AFLP-markers have been taken from plants selected from the group consisting of wheat, barely, maize, tomato, pepper, lettuce and rice.

Please amend claim 12 as follows:

12. (Amended) The array according to claim 6 in which AFLP-markers have been taken from the human genome.

Please amend claim 13 as follows:

13. (Amended) The array according to claim 12, in which the AFLP-markers are representative for the presence, the absence or the state of a genetically determined or influenced disease.

Please amend claim 14 as follows:

14. (Amended) The array according to claim 1 in which the restriction fragments have been generated from one or more cDNAs.

Please amend claim 15 as follows:

15. (Amended) Method for providing an array of nucleic acid sequences bound to a carrier comprising the steps

In re I.A. No.: PCT/NL99/00743  
In re Serial No.: 09/857,408 (Nationalized)

of:

- a) identifying an AFLP-marker;
- b) providing a nucleic acid sequence that comprises a restriction fragment sequence corresponding to said AFLP-marker;
- c) attaching the nucleic acid sequence to the carrier; and
- d) repeating steps a) to c) for different AFLP markers to build up an array.

Please amend claim 16 as follows:

16. (Amended) The method according to claim 15, comprising the steps of:
- a) identifying a polymorphic band in an AFLP-fingerprint;
  - b) isolating a nucleic acid sequence from said polymorphic band;
  - c) optionally further amplifying, purifying and/or modifying the nucleic acid sequence; and
  - d) attaching the nucleic acid sequence to the carrier;
  - e) repeating steps a) to d) for different polymorphic bands to build up an array.

Please amend claim 17 as follows:

17. (Amended) A method for providing an array of nucleic acid sequences bound to a carrier comprising the steps

In re I.A. No.: PCT/NL99/00743  
In re Serial No.: 09/857,408 (Nationalized)

of:

- a) providing a nucleic acid sequence that comprises at least one restriction fragment that has been derived from at least one cDNA
- b) attaching the nucleic acid sequence to the carrier; and
- c) repeating steps a) and b) for different cDNA-derived restriction fragments to build up an array.

Please amend claim 18 as follows:

18. (Amended) The method according to claim 17, comprising the steps of:
- a) analysing at least one cDNA using AFLP-methodology to provide a cDNA-AFLP fingerprint, said fingerprint comprising at least one band;
  - b) isolating from at least one of said bands at least one nucleic acid sequence;
  - c) optionally further amplifying, purifying and/or modifying the nucleic acid sequence;
  - d) attaching the nucleic acid sequence to the carrier; and
  - e) repeating steps a) to d) for different bands and/or for different cDNAs to build up an array.

Please amend claim 19 as follows:

19. (Amended) An array, obtained by the method of

claim 15.

Please amend claim 20 as follows:

20. (Amended) Method for analysing a nucleic acid sequence or a mixture of nucleic acids sequences, comprising contacting said nucleic acid or mixture under hybridizing conditions with an array according to claim 1.

Please amend claim 21 as follows:

21. (Amended) The method according to claim 20, in which the nucleic acid sequence or mixture is suspected to comprise at least one sequence that corresponds to a restriction fragment sequence present in the nucleic acid sequences present in the array.

Please amend claim 22 as follows:

22. (Amended) The method according to claim 20 in which the nucleic acid sequence or mixture comprises DNA.

Please amend claim 23 as follows:

23. (Amended) The method according to claim 20 in which the nucleic acid sequence or mixture comprises a mixture of restriction fragments obtained by restricting a genomic DNA with the same frequent cutter restriction enzyme and rare



In re I.A. No.: PCT/NL99/00743  
In re Serial No.: 09/857,408 (Nationalized)

cutter restriction enzyme as used in generating the  
restriction fragment sequences present in the array.

Please amend claim 24 as follows:

24. (Amended) The method according to claim 20 in  
which the mixture of restriction fragments contacted with the  
array has been amplified prior to hybridisation with the  
array.

Please amend claim 25 as follows:

25. (Amended) The method according to claim 23 in  
which the mixture of restriction fragments has been amplified  
using AFLP.

Please amend claim 26 as follows:

26. (Amended) The method according to claim 2 in  
which the nucleic acid sequence or mixture of nucleic acid  
sequences contacted with the array has been derived from an  
individual related to the individual(s) from which the AFLP-  
markers present in the array have been taken.

Please amend claim 27 as follows:

27. (Amended) The method according to claim 26, in  
which the individual from whom the nucleic acid sequence or

mixture of nucleic acid sequences has been derived belongs to the same species as the individual(s) from which the AFLP-marker(s) present in the array have been taken.

Please amend claim 28 as follows:

28. (Amended) The method according to claim 27 wherein an array is used to analyze a nucleic acid sequence or a mixture of nucleic acid sequences derived from plants selected from the group consisting of wheat, barley, maize, tomato, pepper, lettuce, and rice;

wherein the array comprises a carrier and at least two different nucleic acid sequences bound to said carrier, wherein each of the nucleic acid sequences comprises at least one nucleic acid sequence that corresponds to the sequence of a restriction fragment obtained by restricting at least one member of the group consisting of a genomic DNA and at least one cDNA with at least one frequent cutter restriction enzyme and at least on rare cutter restriction enzyme;

wherein the restriction fragments have been derived from genomic DNA in which at least 50% of the nucleic acid sequences bound to the carrier comprise the sequence of a restriction fragment that corresponds to an AFLP-marker taken from individuals belonging to the same species of plant.

In re I.A. No.: PCT/NL99/00743

In re Serial No.: 09/857,408 (Nationalized)

Please amend claim 29 as follows:

29. (Amended) Kit of parts comprising an array according to claim 1 and optionally other components for use with the array selected from the group consisting of restriction enzymes, polymerase(s), adapters, primers, buffers, nucleotides, labels and other detection agents, containers/packaging and manuals.

Please amend claim 30 as follows:

30. (Amended) Non-processed or processed results or data obtainable by analysing a nucleic acid or mixture of nucleic acids with an array according to claim 1 in the form of an image, of a score, of digital or analog data, optionally stored on a suitable data carrier.

In re I.A. No.: PCT/NL99/00743  
In re Serial No.: 09/857,408 (Nationalized)


REMARKS

The present Preliminary Amendment is submitted in order to eliminate multiple dependencies. No limitations are included in the amendment, and none are intended.

In view of the above, it is respectfully submitted that the claims are now in condition for examination, and prompt and favorable consideration are earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

B.   
Anne M. Kornbau  
Registration No. 25,884

Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
AMK:nmp

F:\N\Nederl\Vol 2\PTO\July 26 01 second prelim amend vpo

"Version with markings to show changes"

2. (Amended) ~~Array~~ The array according to claim 1, which comprises at least 10, ~~preferably at least 100, more preferably 1000~~ different nucleic acid sequences bound to the carrier.

3. (Amended) ~~Array~~ The array according to claim 1 or 2, in which each of the different nucleic acid sequences is bound to the carrier in such a way that it is attached to, and corresponds with, a distinct part of the carrier, so as to form an independently detectable area of the array.

4. (Amended) ~~Array~~ The array according to ~~any of the preceding claims,~~ claim 1 in which the density of the different nucleic acid sequences bound to the carrier is in the range of 1-100,00 different sequences/cm<sup>2</sup>, ~~preferably 5-10,000 different sequences/cm<sup>2</sup>, more preferably between 10-1000 different sequences/cm<sup>2</sup>.~~

5. (Amended) ~~Array~~ The array according to ~~any of the preceding claims,~~ claim 1 in which restriction fragment sequences present in the nucleic acid sequences bound to the carrier have a size of 10 to 1200 nucleotides, and ~~may optionally~~ include partial nucleotide sequences obtained by

restricting the restriction fragments generated from the starting genomic DNA and/or cDNA with one or more further restriction enzymes, and/or de novo synthesized oligonucleotides based thereon and/or derived thereof.

6. (Amended) ~~Array~~ The array according to ~~any of the preceding claims, claim 1~~ in which the restriction fragments have been derived from genomic DNA, and in which at least 50%, ~~preferably at least 70%, more preferably at least 90%~~, of the nucleic acid sequences bound to the carrier comprise the sequence of a restriction fragment that corresponds to an AFLP-marker.

7. (Amended) ~~Array~~ The array according to claim 6, comprising a plurality of AFLP-markers taken from a single individual or from a group of related individuals.

8. (Amended) ~~Array~~ The array according to claim 6 ~~or 7~~, comprising several sets of AFLP-markers, in which each set comprises one or more markers taken from a single individual, wherein said sets of one or more markers have been taken from individuals belonging to a group of related individuals.

9. (Amended) ~~Array~~ The array according to ~~any of~~  
~~claims 6-8,~~ claim 6 in which the AFLP-markers have been taken  
from individuals belonging to the same species of plant,  
animal or microorganism.

10. (Amended) ~~Array~~ The array according to ~~any of~~  
~~claims 7-9,~~ claim 7 in which the AFLP-markers have been taken  
from, or are representative for, different subspecies,  
varieties, cultivars or races of the same species.

11. (Amended) ~~Array~~ The array according to claim 9  
~~or 10,~~ in which the AFLP-markers have been taken from plants  
~~including but not limited to~~ selected from the group  
consisting of wheat, barely, maize, tomato, pepper, lettuce ~~or~~  
and rice.

12. (Amended) ~~Array~~ The array according to ~~any of~~  
~~claims 6-9,~~ claim 6 in which AFLP-markers have been taken from  
the human genome.

13. (Amended) ~~Array according to any of claims 1-~~  
~~12, and in particular~~ The array according to claim 12, in  
which the AFLP-markers are representative for the presence,  
the absence or the state of a genetically determined or

influenced disease.

14. (Amended) ~~Array~~ The array according to ~~any of~~  
~~claims 1-5, claim 1~~ in which the restriction fragments have  
been generated from one or more cDNAs.

15. (Amended) Method for providing an array of  
nucleic acid sequences bound to a carrier, ~~in particular an~~  
~~array according to any of the preceding claims~~, comprising the  
steps of:

- a) identifying an AFLP-marker;
- b) providing a nucleic acid sequence that comprises a  
restriction fragment sequence corresponding to said AFLP-  
marker;
- c) attaching the nucleic acid sequence to the carrier; and
- d) repeating steps a) to c) for different AFLP markers to  
build up an array.

16. (Amended) ~~Method~~ The method according to claim  
15, comprising the steps of:

- a) identifying a polymorphic band in an AFLP-fingerprint;
- b) isolating a nucleic acid sequence from said polymorphic  
band;
- c) optionally further amplifying, purifying and/or modifying



the nucleic acid sequence; and  
d) attaching the nucleic acid sequence to the carrier;  
e) repeating steps a) to d) for different polymorphic bands to build up an array.

17. (Amended) ~~Method~~ A method for providing an array of nucleic acid sequences bound to a carrier, ~~in particular an array according to any of the preceding claims,~~ comprising the steps of:

- a) providing a nucleic acid sequence that comprises at least one restriction fragment that has been derived from at least one cDNA
- b) attaching the nucleic acid sequence to the carrier; and
- c) repeating steps a) and b) for different cDNA-derived restriction fragments to build up an array.

18. (Amended) ~~Method~~ The method according to claim 17, comprising the steps of:  
a) analysing at least one cDNA using AFLP-methodology to provide a cDNA-AFLP fingerprint, said fingerprint comprising at least one, ~~and usually a plurality, of bands~~ band;  
b) isolating from at least one of said bands at least one nucleic acid sequence;  
c) optionally further amplifying, purifying and/or modifying the nucleic acid sequence;

d) attaching the nucleic acid sequence to the carrier; and  
e) repeating steps a) to d) for different bands and/or for  
different cDNAs to build up an array.

19. (Amended) ~~Array~~ An array, ~~obtainable~~ obtained by the  
method of ~~any of claims 15-18~~ claim 15.

20. (Amended) Method for analysing a nucleic acid  
sequence or a mixture of nucleic acids sequences, comprising  
contacting said nucleic acid or mixture under hybridizing  
conditions with an array according to ~~any of claims 1-14 or 19~~  
~~or obtained according to the method of any of claims 15-18~~  
claim 1.

21. (Amended) ~~Method~~ The method according to claim  
20, in which the nucleic acid sequence or mixture is suspected  
to comprise at least one sequence that corresponds to a  
restriction fragment sequence present in the nucleic acid  
sequences ~~present in the array, more specifically to an AFLP-~~  
~~marker~~ present in the array.

22. (Amended) ~~Method~~ The method according to claim  
20 ~~or 21~~, in which the nucleic acid sequence or mixture  
comprises DNA, ~~in particular genomic DNA or a mixture of~~

~~restriction fragments derived from genomic DNA.~~

23. (Amended) ~~Method~~ The method according to ~~any of~~  
~~claims 20-22,~~ claim 20 in which the nucleic acid sequence or  
mixture comprises a mixture of restriction fragments obtained  
by restricting a genomic DNA with the same frequent cutter  
restriction enzyme and rare cutter restriction enzyme as used  
in generating the restriction fragment sequences present in  
the array.

24. (Amended) ~~Method~~ The method according to ~~any of~~  
~~claims 20-23,~~ in claim 20 in which the mixture of restriction  
fragments contacted with the array has been amplified prior to  
hybridisation with the array.

25. (Amended) ~~Method~~ The method according to claim  
~~23-or-24,~~ in which the mixture of restriction fragments has  
been amplified using AFLP, ~~preferably using the same~~  
~~(selective) primers as used in generating the restriction~~  
~~fragments sequences present in the array.~~

26. (Amended) ~~Method~~ The method according to ~~any of~~  
~~claims 20-25,~~ ~~preferably using an array according to any of~~  
~~claims 6-13,~~ claim 2 in which the nucleic acid sequence or

mixture of nucleic acid sequences contacted with the array has been derived from an individual related to the individual(s) from which the AFLP-markers present in the array have been taken.

27. (Amended) ~~Method~~ The method according to claim 26, in which the individual from whom the nucleic acid sequence or mixture of nucleic acid sequences has been derived belongs to the same species as the individual(s) from which the AFLP-marker(s) present in the array have been taken.

28. (Amended) ~~Method~~ The method according to claim 27, ~~in which, wherein~~ an array according to claim 11 is used to ~~analyse~~ analyze a nucleic acid sequence or a mixture of nucleic acid sequences derived from plants ~~including but not limited to~~ selected from the group consisting of wheat, barley, maize, tomato, pepper, lettuce ~~or rice.~~ , and rice;

wherein the array comprises a carrier and at least two different nucleic acid sequences bound to said carrier, wherein each of the nucleic acid sequences comprises at least one nucleic acid sequence that corresponds to the sequence of a restriction fragment obtained by restricting at least one member of the group consisting of a genomic DNA and at least

one cDNA with at least one frequent cutter restriction enzyme  
and at least on rare cutter restriction enzyme;

wherein the restriction fragments have been derived  
from genomic DNA in which at least 50% of the nucleic acid  
sequences bound to the carrier comprise the sequence of a  
restriction fragment that corresponds to an AFLP-marker taken  
from individuals belonging to the same species of plant.

29. (Amended) Kit of parts comprising an array  
according to ~~any of claims 1-14 or 19,~~ claim 1 and optionally  
other components for use with the array, ~~such as selected from~~  
the group consisting of restriction enzymes, polymerase(s),  
adapters, primers, buffers, nucleotides, labels ~~or and~~ other  
detection agents, containers/packaging and manuals.

30. (Amended) Non-processed or processed results or  
data obtainable by analysing a nucleic acid or mixture of  
nucleic acids with an array according to ~~any of claims 1-14 or~~  
~~19, or by a method according to any of claims 20-28, for~~  
~~instance~~ claim 1 in the form of an image, of a score, of  
digital or analog data, optionally stored on a suitable data  
carrier, ~~including paper, photographic film, computer disc or~~  
~~files, or as a database.~~

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: VOS 2

In re Application of:	)	Art Unit:
Petrus Antonius Josephina VOS	)	
et al.	)	Examiner:
	)	
I.A. No.: PCT/NL99/00743	)	Washington, D.C.
	)	
I.A. Filed: 03 December 1999	)	June 4, 2001
	)	
For: ARRAY AND METHOD FOR...	)	

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents and Trademarks  
Washington, D.C. 20231

Sir:

Contemporaneous with the filing of this case and  
prior to calculation of the filing fee, kindly amend as  
follows:

IN THE SPECIFICATION

After the title please insert the following  
paragraph:

REFERENCE TO RELATED APPLICATIONS

--The present application is the national stage  
under 35 U.S.C. 371 of international application  
PCT/NL99/00743, filed 03 December 1999 which designated the  
United States, and which international application was  
published under PCT Article 21(2) in the English language.--

09/857408  
04 JUN 2001  
JC03

[illegible]

## REMARKS

The above amendment to the specification is being made to insert reference to the PCT application of which the present case is a U.S. national stage.

Favorable consideration is earnestly solicited.

Respectfully submitted,  
BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant

By:

Roger L. Browdy  
Registration No. 25,618

RLB:wrd

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

Array and method for analysing nucleic acid sequences.

The present invention relates to arrays for analysing nucleic acid sequences and to methods for analysing nucleic acid sequences using such an array.

5 In particular, the invention relates to arrays and methods for determining whether a specific nucleic acid sequence is present or absent in a nucleic acid sequence or mixture of nucleic acid sequences.

10 More in particular, the invention relates to an array and a method for determining the presence or absence, in genomic DNA or a sample of restriction fragments derived from genomic DNA, of sequences corresponding to unique restriction fragments that can serve as genetic markers, such as AFLP-markers.

The invention further relates to a method for preparing such an array, in particular in the form of a high density array for the detection of biological molecules, herein referred to as a "biochip".

15 A number of methods for analyzing nucleic acid sequences are known. In general, these methods comprise immobilization of the sequences to be analysed, for instance by blotting; hybridization of the sequences with a labeled DNA- or RNA-probe; stringency washes to remove non-hybridized material; followed by detection of those sequences that have hybridized with the probe.

20 Such techniques are often carried out after prior amplification -such as by PCR- of the starting nucleic acid sequences, usually a mixture of restriction fragments from a genomic DNA. The resulting mixture of amplified fragments is then separated, for instance on the basis of differences in length or molecular weight, such as by gel-electrophoresis, and then visualised, i.e. by blotting followed by hybridization. The  
25 resulting pattern of bands is referred to as a DNA fingerprint.

Usually in DNA fingerprinting, fingerprints of closely related species, subspecies, varieties, cultivars, races or individuals are compared. Such related fingerprints can be identical or very similar, i.e. contain a large number of corresponding -and therefore less informative- bands.

30 Differences between two related fingerprints are referred to as "DNA polymorphisms". These are DNA fragments (i.e. bands) which are unique in or for a



fingerprint and/or for a subset of fingerprints. The presence or absence of such polymorphic bands, or the pattern thereof, can be used as a genetic marker, i.e. to identify a specific species, subspecies, variety, cultivar, race or individual, to establish the presence or absence of a specific inheritable trait, of a gene, or to determine the state of a disease.

For a further discussion and definitions of DNA-fingerprinting, DNA typing, DNA polymorphisms, genotyping, PCR and similar techniques, reference is made to the discussion of the prior art in EP-0 534 858 A1, incorporated herein by reference.

The abovementioned hybridization-based techniques require at least some prior knowledge of the sequence to be analysed, i.e. sufficient to provide a probe that can hybridize with the desired sequence(s). Such a probe must also be sufficiently selective to afford informative results. For instance, when analysing a plant genome, a probe that hybridizes with the "repeated" sequences within the genome will generally not provide any useful results, as such repeated sequences preclude typing unique polymorphisms.

A DNA-fingerprinting technique which requires no prior knowledge of the sequence to be analysed is described in the European patent application 0 534 858 by applicant, incorporated herein by reference. This technique, called selective restriction fragment amplification or AFLP, in general comprises the steps of:

- (a) digesting a nucleic acid, in particular a DNA, with one or more specific restriction endonucleases, to fragment said DNA into a corresponding series of restriction fragments;
- (b) ligating the restriction fragments thus obtained with at least one double-stranded synthetic oligonucleotide adapter, one end of which is compatible with one or both of the ends of the restriction fragments, to thereby produce tagged restriction fragments of the starting DNA;
- (c) contacting said tagged restriction fragments under hybridizing conditions with at least one oligonucleotide primer;
- (d) amplifying said tagged restriction fragment hybridized with said primers by PCR or a similar technique so as to cause further elongation of the hybridized primers along the restriction fragments of the starting DNA to which said

- primers hybridized; and
- (e) identifying or recovering the amplified or elongated DNA fragment thus obtained.

5 The thus amplified DNA-fragments can then be analysed and/or visualised, for instance by means of gel-electrophoresis, to provide a genetic fingerprint showing bands corresponding to those restriction fragments that have been linked to the adapter, recognized by the primer, and therefore amplified during the amplification step.

10 The AFLP-fingerprint thus obtained provides information on the specific restriction site pattern of the starting DNA. By comparing AFLP-fingerprints from related individuals, bands which are unique for each fingerprint can be identified. These polymorphisms are referred to as "AFLP-markers", and can again be used to identify a specific individual, cultivar, race, variety, subspecies or species, and/or to establish the presence or absence of a specific inherited trait, gene or disease state.

15 AFLP thus requires no prior knowledge of the DNA sequence to be analysed, nor prior identification of suitable probes and/or the construction of a gene library from the starting DNA.

20 For a further description of AFLP, its advantages, its embodiments, as well as the techniques, enzymes, adapters, primers and further compounds and tools used therein, reference is made to EP-A-0 534 858 and co-pending European applications 98.202.5496 and 98.202.4515, all by applicant and incorporated herein by reference. Also, in the description hereinbelow, the definitions given in paragraph 5.1 of EP-0 534 858 will be used, unless indicated otherwise.

25 Although AFLP is generally less time-consuming than hybridisation-based techniques, it still suffers from the disadvantage that the amplified fragments have to be separated (i.e. by gel-electrophoresis) and visualized (i.e. by generation of a fingerprint). These are very elaborate and time consuming procedures, which require special apparatus, such as electrophoresis and auto-radiography equipment. Thereafter, the fingerprints have to be analysed -nowadays generally performed by "reading" the fingerprint into a computer- to identify the polymorphic bands. Generally, this also  
30 requires to use of a known reference sample run at the same time in a parallel lane of the gel.

5

A first aim of the invention is therefore to simplify these procedures, i.e. to provide a technique for analysing nucleic acid sequences which no longer requires the use of gel-electrophoresis and/or autoradiography.

10

15

20

30

According to the invention, this is carried out by analysing the genomic DNA of two or more related individuals using AFLP, identifying polymorphisms ("AFLP-markers") within the genome, amplifying and isolating the nucleic acid sequences corresponding to these AFLP-markers, and binding the amplified sequences to specific areas of a carrier, thus providing an array comprising essentially only nucleic acid sequences that correspond to AFLP-markers.

This array can then be used to analyse a sample of nucleic acid(s) -such as a genomic DNA or restriction fragments thereof- derived from the same or a genetically related individual, by contacting the sample with the array under hybridizing conditions. The nucleic acid sequence(s) to be analysed will then (only) hybridize with those parts of the array that carry an essentially homologous sequence, i.e. the same AFLP-marker, or at least a sequence with a high degree of homology with the marker. Thus, by analysing to which parts of the array (i.e. to which AFLP-markers) the nucleic acid sequence(s) to be analysed has or have hybridized, the presence of absence of said marker in the sample can be established.

In other words, the invention makes it possible to test a sample of nucleic acid(s) directly for the presence of a large number of polymorphic fragments or bands - i.e. as many as are bound to the carrier- without the need of generating and analysing a DNA-fingerprint.

The invention also makes it possible to test simultaneously for a large number of "unrelated" markers (i.e. markers which can normally not be detected in a single AFLP-reaction or fingerprint) by incorporating these different markers into a single array.

Other objects and advantages of the invention will become clear from the description hereinbelow.

H. Himmelbauer et al., Mammalian Genome 9, 611-616 (1998) describe a method for the identification and mapping of polymorphic markers, using "a modification of the AFLP technique" called the "IRS-PCR system". According to this method, genomic (mouse) DNA is restricted using a single restriction enzyme (*SacI* or *BamHI*), amplified in a PCR using adapters and primers, after which the amplicons thus obtained are hybridized with a gridded genomic library (BAC-clones) to identify

strain-specific differences. Positive clones can then be used to generate genotyping information, i.e. by hybridizing fragment mixtures derived from individuals of a backcross population against the positive clones, or by amplifying individual clones for hybridization against the complex fragment mixtures derived from individuals of a backcross population.

In the invention, compared to the method of Himmelbauer, the markers are generated by restricting with two restriction enzymes, i.e. a rare and a frequent cutter. Also, the invention does not require the preparation of a BAC-library, nor of a subsequent hybridization against a backcross.

Also, Himmelbauer et al. do not suggest to use the IRS-PCR- derived clones in an array. The array used by Himmelbauer, a high density spotted filter grid of genomic BAC-clones, is prepared using conventional complex probe hybridization. Also, this array is not (and cannot be) used to scan a DNA sample directly for the presence of markers. Instead, this grid is used in the identification of markers (i.e. by further hybridisation with a backcross), which markers are then used for genome mapping.

The art also describes oligonucleotide arrays, vide for instance WO 97/27317, WO 97/22720, WO 97/43450, EP 0 799 897, EP 0 785 280, WO 97/31256, WO 97/27317 and WO 98/08083.

Such arrays, which include the Genechips<sup>TM</sup> array, the Affymetrix DNA chip and the VLSIPS<sup>TM</sup> array, can have nucleotide densities of more than 100-10.000 per cm<sup>2</sup> or more and are generally prepared by "building up" the oligonucleotides on the solid support using sequential solid phase nucleic acid synthesis techniques. However, as this is difficult and time-consuming, even when using automated equipment, there is a practical limit to the size of the oligonucleotides on the array, i.e. of about 100 nucleotides, usually about 10-50 nucleotides, usually without variation in size. The use of such small oligonucleotides can lead to a relatively large occurrence of mismatch events, which reduces selectivity and increases the background noise.

Because of this, these known arrays generally require several of the attached oligonucleotides to detect a target sequence. Also, they do not directly provide data on the presence of specific markers, but require substantive analysis of the signal pattern,

usually by comparison to known results or a reference using sophisticated computer algorithms.

In a first aspect, the present invention relates to an array for analysing a nucleic acid sequence or a mixture of nucleic acid sequences, comprising:

- 5 a) a carrier; and
- b) at least two different nucleic acid sequences bound to said carrier, in which each of the nucleic acid sequences bound to the carrier comprises at least a nucleic acid sequence that corresponds to the sequence of a restriction fragment obtainable by restricting a genomic DNA with at least one frequent  
10 cutter restriction enzyme and at least one rare cutter restriction enzyme.

More particular, the invention relates to such an array in which at least 50%, preferably at least 70%, more preferably at least 90% of the nucleic acid sequences bound to the carrier comprise the sequence of a restriction fragment that corresponds to an AFLP-marker.

15 In a further aspect the invention relates to a method for providing an array of nucleic acid sequences bound to a carrier, comprising the steps of:

- a) identifying an AFLP-marker;
- b) providing a nucleic acid sequence that comprises a restriction fragment  
sequence corresponding to said AFLP-marker;
- 20 c) attaching the nucleic acid sequence to the carrier; and
- d) repeating steps a) to c) for different AFLP markers to build up an array.

More particularly, the invention relates to such a method comprising the steps

of:

- a) identifying a polymorphic band in an AFLP-fingerprint;
- 25 b) isolating a nucleic acid sequence from said polymorphic band;
- c) optionally further amplifying, purifying and/or modifying the nucleic acid sequence; and
- d) attaching the nucleic acid sequence to the carrier.
- e) repeating steps a) to d) for different polymorphic bands to build up an array.

30 In a yet another aspect, the starting DNA used to generate the restriction fragments that are bound to the carrier are not derived from genomic DNA, but from at

least one cDNA. Generally, an array according to this aspect of the invention comprises:

- a) a carrier; and
- b) at least two different nucleic acid sequences bound to said carrier, in which each of the nucleic acid sequences bound to the carrier comprises at least a nucleic acid sequence that corresponds to the sequence of a restriction fragment obtainable by restricting at least one cDNA with at least one frequent cutter restriction enzyme and at least one rare cutter restriction enzyme.

A method of the invention for preparing such a cDNA-based array generally comprises the steps of:

- a) providing a nucleic acid sequence that comprises at least one restriction fragment that has been derived from at least one cDNA.
- b) attaching the nucleic acid sequence to the carrier; and
- c) repeating steps a) and b) for different cDNA-derived restriction fragments to build up an array.

More particularly, the invention relates to such a method comprising the steps of:

- a) analysing at least one cDNA using AFLP-methodology to provide a cDNA-AFLP-fingerprint, said fingerprint comprising at least one, and usually a plurality, of bands;
- b) isolating from at least one of said bands at least one nucleic acid sequence;
- c) optionally further amplifying, purifying and/or modifying the nucleic acid sequence; and
- d) attaching the nucleic acid sequence to the carrier.
- e) repeating steps a) to d) for different bands and/or for different cDNAs to build up an array.

In yet another aspect, the invention relates to method for analysing a nucleic acid (sequence) or a mixture of nucleic acids (nucleic acid sequences), comprising contacting said nucleic acid or mixture with an array as described herein.

Other aspects and embodiments of the invention will become clear from the description and experimental part hereinbelow.

In the description, the nucleic acid sequences bound to the carrier will be indicated as "*Array-bound Nucleic Acid Sequence(s)*" or "ÄNAS", and the restriction fragments present therein will be indicated as "*Restriction Fragment Sequence(s)*" or "RFS". Usually, each Array-bound Nucleic Acid Sequences will comprise (only) one Restriction Fragment Sequence, and optionally further nucleic acid sequences or structural elements as described below, bound to the Restriction Fragment Sequence. When Array-bound Nucleic Acid Sequences are referred to hereinbelow as "different", it means that these Array-bound Nucleic Acid Sequences contain different Restriction Fragment Sequences.

The array preferably comprises at least 10, more specifically at least 100, more preferably at least 1000 different Array-bound Nucleic Acid Sequences. For a "high-density array" or "micro-array", the total number of Array-bound Nucleic Acid Sequences will be in the region of 100 - 100.000.

These Array-bound Nucleic Acid Sequences will generally be bound to the carrier in such a way that each Array-bound Nucleic Acid Sequence is attached to, and corresponds with, a specific, distinct part of the carrier, so as to form an independently detectable area on the carrier, such as a spot or band. This makes it possible to "read" the array by scanning (i.e. visually or otherwise) the areas to which the Array-bound Nucleic Acid Sequence (i.e. the marker) of interest is attached.

Preferably, the Array-bound Nucleic Acid Sequences are bound to the carrier in accordance with a predetermined, regularly distributed pattern, in which for instance related Array-bound Nucleic Acid Sequence (i.e. related markers) can be grouped together, i.e. in one or more lines, columns, rows, squares, rectangles, etc, preferably in an "adressable" form. This further facilitates analysis of the array.

The density of the different Array-bound Nucleic Acid Sequences will generally be in the region of 1-100,000 different markers/cm<sup>2</sup>, usually 5-50,000 markers/cm<sup>2</sup>, generally between 10-10,000 markers/cm<sup>2</sup>.

In general, each of the Array-bound Nucleic Acid Sequences on the array will correspond to a specific polymorphic band or marker, i.e. as derived from an AFLP-fingerprint of genomic DNA of a specific individual. Usually, the array will comprise sets of one or more of such markers taken from a single fingerprint, or at least taken



from fingerprints of a single individual.

Often, the array will be build up of one or more of such individual sets, each taken from an AFLP-fingerprint of a different but related individual. By "related individuals" is meant herein that these individuals are such that useful or desired information can be obtained by comparing their DNA-fingerprints, more specifically their AFLP-fingerprints. Usually, this means that these individuals share or have related inherited properties or traits (including genetic markers) and/or have nucleic acid sequences in their genome (such as genes) which are the same or related. In practice, related individuals will usually stem from the same family, genus, species, subspecies, variety, cultivar or race, depending upon the purpose of the comparison.

In the array's of the invention, the markers taken from one individual, and the sets of markers taken from related individuals, will usually be arranged on the array in a predetermined, regular pattern.

Usually, the markers will be derived from a limited number of related individuals, which have been selected in such a way that they represent the genetic diversity within the group of interest (i.e. family, genus, species, subspecies, cultivar, race or variety) in the best possible way. This selected set of individuals is called the "genotyping collection".

Preferably the array will contain a majority or even all the markers from a genotyping collection that are characteristic for the presence or absence of the one or more traits or properties of interest. For instance, an array may contain all or most markers characteristic for the dominant, the recessive and any or all allelic forms of one or more genes or traits of interest, as may be present within different individuals from the same family, genus or species.

An array of the invention can (also) contain sets of markers that correspond to different (i.e. genetically unrelated) traits or properties, and such an array can be used to analyse an individual (genome) for the presence or absence of all these properties simultaneously. However, such unrelated markers will usually still have been obtained from within one genotyping collection, i.e. from individuals belonging to the same family, genus or preferably species, i.e. so as to provide -for instance- a "maize-array", a "tomato-array", a "wheat-array" etc..

In one embodiment, the AFLP-markers present on the array have been taken from or will be representative of different subspecies, varieties, cultivars, lines or races of the same species.

5 An array of the invention can also contain markers representative of a certain genetic state of an individual, such as the presence or absence of a disease state, i.e. of oncogenes and of genetically determined diseases.

As already mentioned above, besides arrays based on restriction fragments derived from genomic DNA - e.g. based on polymorphic fragments/genetic markers - the invention also provides arrays based on (restriction fragments derived from) cDNA.

10 According to this aspect of the invention, the RFS present in the ANAS will be a restriction fragment obtained by restricting at least one cDNA with at least one restriction enzyme, and preferably with at least one frequent cutter restriction enzyme and at least one rare cutter restriction enzyme as described herein.

Usually, prior to attachment to the array, the cDNA-derived restriction  
15 fragments thus obtained are amplified, preferably using AFLP. Such AFLP-amplification of cDNA is generally referred to as "cDNA-AFLP" and can be carried out essentially as described above for the AFLP-amplification of genomic DNA and/or by using any cDNA-AFLP protocol known per se, to provide a cDNA-derived AFLP-fingerprint.

20 One or more of the bands from this cDNA-AFLP fingerprint may then be isolated from the gel and bound to the array, e.g. after re-amplification and/or incorporation into an ANAS, essentially as described for the genomic DNA.

This may be carried out for different bands obtained from the same cDNA, and/or for bands from one or more different cDNAs. Also, the one or cDNAs used to  
25 provide the RFS may be obtained from (mRNAs derived from) one individual ( e.g. from different cells, parts, tissues or organs) and/or from two or more individuals, e.g. individuals belonging to same race, variety, species, genus, family etc., with the same or different phenotypical characteristics. Also, the cDNAs may be obtained from (mRNA derived from) healthy individuals and/or from diseased individuals; and/or  
30 from individuals at different stages of development.

Furthermore, although the genomic DNA based arrays and the cDNA based

arrays are discussed separately hereinabove, it will be clear to the skilled person that an array of the invention may also contain both one or more restriction fragments derived from genomic DNA as well as one or more restriction fragments derived from cDNA.

Although preferably, each Array-bound Nucleic Acid Sequence on the array will correspond to a polymorphic band of interest ( i.e. a marker) or an informative cDNA-derived band, the presence on the array of some non or less informative Array-bound Nucleic Acid Sequences (for instance corresponding to non-polymorphic bands or to markers that are too abundant to provide useful information) is not excluded. However, these will preferably constitute less than 50%, preferably less than 30%, more preferably less than 10% of all Array-bound Nucleic Acid Sequences present on the array. It is also included that some or most of the Array-bound Nucleic Acid Sequences may be informative for one specific application or genome, but not for another. However, preferably 95-100% of all Array-bound Nucleic Acid Sequences will correspond to or contain an AFLP-marker.

The manner in which the Array-bound Nucleic Acid Sequences and the Restriction Fragment Sequences are obtained is further described in the Experimental Part below.

In general, the Restriction Fragment Sequences are characterized in that they are obtainable/obtained by cutting a starting DNA, usually a genomic DNA or cDNA, with at least one "frequent cutter" restriction enzyme and at least one "rare cutter" restriction enzyme. These fragments are then bound to adapters and amplified using (usually selective) primers. The thus amplified fragments are visualized in a DNA-fingerprint, and polymorphic bands are identified, i.e. by comparison with the fingerprint(s) of one or more related individuals or to a database. The restriction fragments present in these polymorphic bands are then individually isolated (by cutting them out from the gel) and optionally further purified and/or amplified, after which they are attached to a specific, distinct area of the carrier, optionally after modification of carrier surface and/or of the fragment to allow or promote such attachment.

Therefore, generally speaking, the invention uses AFLP-methodology both to select and to prepare (i.e. to amplify and to isolate) the nucleic acid sequences to be attached to the array, and to do so simultaneously. The use of AFLP in the invention

also makes it possible to identify and prepare, at the same time, markers from related individuals (i.e. from one genotyping collection) i.e. by running parallel AFLP-reactions and visualizing these reactions in adjacent lanes of the same gel. In this way, a micro-array containing a large number of markers and/or containing all relevant markers from a genotyping collection can be build up very efficiently.

As in AFLP, two different restriction enzymes are used to digest the starting (genomic) DNA, i.e. the "frequent cutter", which serves the purpose of reducing the size of the restriction fragments to a range of sizes which are amplified efficiently, and the "rare cutter" which serves the purpose of targeting rare sequences. For both, reference is made to EP-A-0 534 858 and EP-A-0 721 987 by applicant, incorporated herein by reference.

Examples of suitable frequent cutter enzymes are *MseI* and *TaqI*. Examples of commercially available rare cutters are *PstI*, *HpaII*, *MspI*, *Clal*, *HhaI*, *EcoRII*, *BstBI*, *HinPI*, *MaeII*, *BbvI*, *PvuII*, *XmaI*, *SmaI*, *NciI*, *AvaI*, *HaeII*, *SalI*, *XhoI* and *PvuII*, of which *PstI*, *HpaII*, *MspI*, *Clal*, *EcoRII*, *BstBI*, *HinPI* and *MaeII* are preferred.

The AFLP-reaction will usually be carried out following known protocols, for which reference is made to EP-A-0 534 858, incorporated herein by reference.

The Restriction Fragment Sequence (with the AFLP-adapters) will generally have a size that can be detected as an individual band in an AFLP-fingerprint, i.e. in the range of 50 - 1200 base pairs. It will be clear that, as the Restriction Fragment Sequence are separated by gel-electrophoresis, they will be of different sizes.

Also, it may be possible to use as the Restriction Fragment Sequence only a part of a restriction fragment obtained as/from a band in the AFLP fingerprint. Such a partial sequence may for instance be obtained by (further) restricting the restriction fragment(s) isolated from the AFLP gel with one or more restriction enzymes, i.e. usually with other restriction enzymes than the one or two originally used to generate the restriction fragments from the starting genomic or cDNA, including but not limited to synthesized oligonucleotides based and/or derived thereof. For this purpose, any desired and/or pre-determined restriction enzyme or enzyme combination may be used; suitable restriction enzymes include, but are not limited to, the frequent cutters and rare cutters mentioned above, IIS-type restriction enzymes.

In general, such a partial sequence generated by (further) restricting the restriction fragments obtained from the AFLP gel may have any suitable size, up to the size of the original restriction fragment (i.e. when no recognition site for the restriction enzyme used is present in the restriction fragment). Usually, however, these partial sequences will be smaller than the restriction fragments, i.e. the range of 10 – 100 base pairs.

The use of such smaller, but still specific, partial sequences may have some advantages, such as avoiding cross-hybridization between sequences showing homologous regions. Also, for the purposes of the description herein, such partial sequences should be considered as encompassed within the term "Restriction Fragment Sequence" as used herein.

Preferably, the Array-bound Nucleic Acid Sequence comprises single-stranded DNA, although the use of double-stranded DNA as Array-bound Nucleic Acid Sequences is also within the scope of the invention.

The Array-bound Nucleic Acid Sequence will at least comprise one (and usually only one) Restriction Fragment Sequence, and can further contain other sequences or structural elements, often at the end(s) of the Restriction Fragment Sequence-sequence. These include AFLP-adaptor sequences (one or two) and/or other nucleic acid sequences, as well as groups or functionalities that can be used for attaching the Array-bound Nucleic Acid Sequence to the array (hereinbelow referred to as "binding elements").

The adaptor sequences will usually be present at the end(s) of the Array-bound Nucleic Acid Sequence, and may be the adaptors used in the AFLP-reaction with which the original genomic DNA as amplified, and/or used to amplify the sample to be analysed. However, they preferably contain (adaptor) sequences different thereto, for the reasons given in the Experimental Part below.

The adaptors may also have been modified to contain groups or functionalities that can be used for attaching the Array-bound Nucleic Acid Sequence to the array, so as to make the adaptor into a binding element.

The binding elements may be present at the end(s) of the Restriction Fragment Sequences (i.e. replacing the adaptors) but may also be present in or on the Restriction

Fragment Sequence itself, depending upon the technique used for binding the Array-bound Nucleic Acid Sequence to the array, as further described below.

The carrier for the array may be any solid material to which nucleic acid sequences can be attached, including porous, fibrous, woven and non-woven materials, as well as composite materials. Also, semi-solid materials such as gels or matrices (for instance as used in chromatography) may be used, although this is not preferred.

Suitable carriers include, but are not limited to, those made of plastics, resins, polysaccharides, silica or silica-based materials, functionalized glass, modified silicon, carbon, metals, inorganic glasses, membranes, nylon, natural fibers such as silk, wool and cotton, and polymer materials such as polystyrene, polyethylene glycol tetraphthalate, polyvinyl acetate, polyvinyl chloride, polyvinyl pyrrolidone, polyacrylonitrile, polymethyl methacrylate, polytetrafluoroethylene, butyl rubber, styrenebutadiene rubber, natural rubber, polyethylene, polypropylene, (poly)tetrafluoroethylene, (poly)vinylidene fluoride, polycarbonate and polymethylpentene. Further suitable support materials are mentioned for instance mentioned in US-A-5,427,779, WO 97/22720, WO 97/43450, WO 97/31256, WO 97/27317 and EP 0 799 897.

Preferred carrier materials are glass and silicon.

Preferably, the carrier will have an essentially flat, rectangular shape, with the Array-bound Nucleic Acid Sequences bound to one surface thereof. However, any other suitable two- or three-dimensional form may also be used, such as a disc, a sphere or beads, or materials or structures that allow a liquid medium containing the sample to be analysed to pass or flow through the carrier, such as columns, tubes or capillaries, as well as (macro)porous, web- or membrane-type structures, including the flow-through genosensor devices referred to in WO 97/22720.

The size of the array, as well as of the individual areas corresponding to each of the different Array-bound Nucleic Acid Sequences, may vary, depending upon the total amount of Array-bound Nucleic Acid Sequence, as well as the intended method for analysing the array.

For an array that is to be inspected visually, the total array and the separate areas thereon will be of such a size that they can be seen and distinguished with the naked eye or through a microscope, i.e. in the range of 1 to 500 cm<sup>2</sup> for the total array,

and 0.01 to 0.1 cm<sup>2</sup> for the individual areas.

Arrays that are analysed using other types of (usually automated) scanning equipment may be of smaller size, and are preferably in the form of high-density or micro-arrays, i.e. in the range of 1 - 10 cm<sup>2</sup> for the total array, 0.001 - 0.1 cm<sup>2</sup> for the individual areas. This allows hybridization to be carried out in a small volume on a small sample, or even the use of flow-through techniques.

The Array-bound Nucleic Acid Sequences may be bound to the carrier in any manner known per se, and the specific technique used will mainly depend upon the carrier used. Binding may be at the 3'-end, at the 5'-end, or somewhere else on the Restriction Fragment Sequence/Array-bound Nucleic Acid Sequence, as appropriate.

Preferably, the Array-bound Nucleic Acid Sequence will be covalently bonded to the array, i.e. by a suitable chemical technique. As mentioned above, for this purpose, the Array-bound Nucleic Acid Sequence and/or the carrier may be modified to carry one or more binding groups or elements. For instance, the surface of the carrier may be activated to carry one or more groups such as carboxy, amino, hydroxy, etc..

Suitable methods for attaching the Array-bound Nucleic Acid Sequences to the carrier will be clear to the skilled person. In general, any method for attaching a nucleic acid to a solid support can be used, including the methods described in US-A-5,427,779; US-A-4,973,493; US-A-4,979,959; US-A-5,002,582; US-A-5,217,492; US-A-5,525,041; US-A-5,263,992; WO 97/46313 and WO 97/22720, as well as the references cited therein.

As an example of covalent attachment, coupling can proceed using photoreactive groups such as N-oxy-succinimide, in which either the Array-bound Nucleic Acid Sequence is derivatized with a photoreactive group and attached to the surface, or the surface is first treated with a photoreactive group, followed by application of the Array-bound Nucleic Acid Sequence, for instance in N-terminal amino-modified form. A suitable protocol, following the general method described in Amos et al., Surface Modification of Polymers by Photochemical Immobilization, The 17th Annual Meeting of the Society of Biomaterials, May 1991, Scottsdale AZ, given in WO 97/46313, incorporated herein by reference.

Other covalent binding techniques involve the use of 3'-aminopropanol-groups

or epoxysilane-amine chemistry, for instance as described in WO 97/22720, also incorporated herein by reference.

5       An example of a strong, but non-covalent binding technique involves the attachment of a biotinylated Array-bound Nucleic Acid Sequence onto a carrier coated with streptavidin.

      In order to create small, distinct, addressable areas of each of the Array-bound Nucleic Acid Sequence on the array, masking techniques or known microdispensing techniques may be used, for instance as described in WO 97/46313 and WO 97/22720.

10       After attachment of the Array-bound Nucleic Acid Sequences to the carrier, the array will generally be ready for use.

15       In a further aspect, the invention relates to a method for analysing a nucleic acid sample using the array of the invention. In general, this method comprises contacting the sample to be analysed with the array under hybridizing conditions, so that the one or more of the nucleic acid sequence(s) present in the sample may bind to the one or more of the Array-bound Nucleic Acid Sequences on the array, more specifically with the Restriction Fragment Sequences present in the Array-bound Nucleic Acid Sequence. This method is described in more detail in the Experimental Part below.

20       Usually, a nucleic acid sequence or mixture will be analysed that is suspected to comprise at least one sequence or fragment that corresponds to a Restriction Fragment Sequence (i.e. an AFLP-marker) present on the array used. In this context, "corresponds" means a sequence homology of at least 70%, more preferably at least 85%, specifically 95%-100%.

25       In general, the method of the invention is based on the hybridisation of sequences in the sample to be analysed with the Restriction Fragment Sequence. In other words, in the invention, the target sample is probed directly with the pre-selected sequences/markers of interest, so that a positive hybridization event or signal is directly indicative of the presence of said marker in the target sample. Also, as these markers are unique sequences with low abundance in the target genome, generally a high  
30       selectivity can be obtained,

      Also, in a highly preferred embodiment of the invention, in analysing a target



genome, said genomic DNA is subjected to "AFLP" prior to hybridisation to the array, in which by "ÄFLP" in this context is more generally meant that the starting DNA is cut using at least one restriction enzyme and then amplified using adapters and primers, of which at least one contains at least one selective base at the 3'-end. This leads to a further reduction of sample complexity, giving less background noise.

Even more preferably, in the AFLP amplification prior to hybridization, the same frequent cutter and rare cutter are used as were used in generating (at least some of) the Restriction Fragment Sequence, and most preferably a similar protocol is followed, using the same (selective) primers. In this way, the amplified sample will contain, and essentially only contain, fragments that exactly correspond to the Restriction Fragment Sequence on the array (i.e. besides further non-polymorphic fragments that are not expected to hybridize with (the RFS on) the array). This improves specificity and reliability even further.

Suitable hybridisation conditions (i.e. buffers used, salt strength, temperature, duration) can be selected by the skilled person, on the basis of experience or optionally after some preliminary experiments. These conditions may vary, depending on factors such the Array-bound Nucleic Acid Sequences present on the array (size of the Restriction Fragment Sequence, CG-content etc.), and the sample to be analysed.

Suitable hybridisation conditions are for instance described in Sambrook et al., *Molecular Cloning: A Laboratory manual*, (1989) 2nd. Ed. Cold Spring Harbour, N.Y.; Berger and Kimmel, "Guide to Molecular Cloning Techniques", *Methods in Enzymology*", (1987), Volume 152, Academic Press Inc., San Diego, CA; Young and Davis (1983) *Proc. Natl. Acad. Sci.(USA)* 80: 1194; *Laboratory Techniques in Biochemistry and Molecular Biology, Vol.24, Hybridization with Nucleic Acid Probes*, P. Thijssen, ed., Elsevier, N.Y. (1993), as well as WO 97/43450, EP-A-0 799 897, WO 97/27317, WO 92/10092, WO 95/1195, WO 97/22720 and US-A-5,424,186, all incorporated herein by reference.

Suitable hybridisation conditions comprise temperatures between 25-70°C, preferably 35-65°C, a duration of between 1 minute and 30 hours, preferably about 30 minutes to 2 hours, and using known hybridization buffers, such as salt-, Tris- or citrate- containing buffers, etc., and may for example vary from 6X SSPE-T at about

40°C to 1X SSPE-T at 37°C down to as low as 0.25X SSPE-T at 37-50°C.

The hybridisation conditions are preferably chosen such that only those nucleic acid sequences in the target sample that have more than 70%, preferably more than 80%, more preferably more than 90% homology, and in particular 95-100% homology with the Restriction Fragment Sequences, will hybridize with the Array-bound Nucleic Acid Sequence. These will generally be "moderate" or preferably "stringent" hybridisation conditions. Such stringent conditions can be as described in EP 0 799 897.

After hybridization, the array is washed to remove unwanted compounds, in particular any nucleic acid sequences not hybridized with the Array-bound Nucleic Acid Sequences on the array. Thereafter, the array is analysed to determine to which areas on the array (i.e. to which Array-bound Nucleic Acid Sequences/Restriction Fragment Sequences) the nucleic acid sequence(s) from the sample has/have hybridized. These area's will generally be detected as a positive signal indicating the presence of the marker in the sample.

The analysis of the array may be carried out in any manner known per se, including optical techniques, spectroscopy, chemical techniques, biochemical techniques, fotochemical techniques, electrical techniques, light scattering techniques, colorimetric techniques, radiography techniques, etc., as long as they can indicate the presence of a hybridization event. Suitable techniques are for instance described in WO 97/27317, WO 97/22720, WO 97/43450, EP 0 799 897, WO 97/31256, WO 97/27317 and WO 98/08083.

Usually, a technique using detectable labels will be used. Such a label will generally be attached to the nucleic acid sequence(s) to be analysed, so that -after hybridization with the array- those areas of the array which show the presence of the label correspond to a positive hybridization event.

Suitable labels are for instance described in WO 97/27317, WO 97/22720, WO 97/43450, EP 0 799 897, WO 97/31256, WO 97/27317 and WO 98/08083 and include fluorescent labels, phosphorescent labels, chemoluminescent labels, bioluminescent labels, chemical labels, biochemical labels such as enzymes, biological labels such as biotin/streptavidin, radioisotopes, spin or resonance labels, metal colloids

such as gold, magnetic beads, chromogens, dyes, and similar labels.

These labels may be incorporated into the target nucleic acids during amplification, for instance by using labelled primers or nucleotides. Also, primers or nucleotides carrying binding groups to which a label subsequently may be attached can be used in the amplification reaction.

Alternatively, the target nucleic acids may be end-labelled after amplification, for instance as described in WO 97/27317. Furthermore, so-called "indirect" labels may be used, which are joined to the target sequence/Array-bound Nucleic Acid Sequence-duplex after hybridisation, again as for instance described in WO 97/27317.

Detection and optionally recording of positive signals on the array is carried out in a manner known per se, usually depending on whether a label is used, and if so, the type thereof. For instance, the array may be inspected visually or by (confocal) microscopy; by spectroscopy; using photographic film, electronic detectors or a CCD camera; by colorimetric or (bio)chemical assay; or by any other suitable method, for which again reference is made to WO 97/27317, WO 97/22720, WO 97/43450, EP 0 799 897, WO 97/31256, WO 97/27317 and WO 98/08083. Automated scanning equipment based upon such techniques may also be used.

Optionally, the relative intensity or absolute magnitude of a positive hybridisation signal for a binding site on the array may be used as a relative indication or an absolute measure of the amount of the corresponding fragment present in the original sample, for instance as described in WO 98/08083.

The analysis of the hybridization (pattern) to the array may as such provide useful results, i.e. show the presence or absence of a genetic marker or genetic trait of interest, identify an individual, or otherwise provide information on the individual analysed, such as to which strain, variety, cultivar or race it belongs. It may also directly indicate the presence or absence of a disease state.

Optionally, the data obtained from "reading" the array may also be processed further, i.e. by comparing it to references, to earlier results or to a database, optionally using computer algorithms.

Advantageously, the array of the invention can be used to replace conventional fingerprinting/autoradiography analysis in AFLP. This aspect of the invention

comprises steps (a) - (e) of the general AFLP-method described above, in which step (e) is carried out by contacting the (mixture of) amplified or elongated DNA fragment(s) obtained in step (d) with an array as described herein.

Compared to conventional fingerprinting/autoradiography, the use of an array generally will be faster than using fingerprinting/autoradiography, and several markers that would require generating several separate fingerprints could be combined into a single array. This makes the arrays of the invention especially suited for routine and/or high throughput screening, for instance in plant breeding.

Also, the array of the invention can conveniently be provided as a kit of parts comprising the array and other components for use with the array, such as restriction enzymes, polymerase(s), adapters, primers, buffers, nucleotides, labels or other detection agents, containers/packaging and manuals. The array of the invention may even be in the form of a hand-held device such as a dipstick.

The array of the invention may be re-usable, usually through regeneration to remove the hybridized sequences. A kit of the invention may therefore also contain agents that can be used for such regeneration.

The array of the invention can be used to analyse any kind of nucleic acid sequence or mixture of nucleic acid sequences, including, but not limited to, plant-derived sequences, animal-derived sequences, human-derived sequences, microbial sequences, yeast sequences, sequences from fungi and algae, and viral sequences, depending upon the origin of the restriction fragment sequences bound to the array, including but not limited to whether the restriction fragments bound to the array are derived from genomic DNA or cDNA (or both).

Also, the array may be used to analyse DNA sequences, including genomic DNA, cDNA, structural genes, regulatory sequences and/or parts thereof; as well as RNA, including mRNA, optionally by analogous modification of the method given above.

The nucleic acid sample analysed with the array may be a sample as isolated directly from a living or dead organism or from tissue or cells. Preferably however, prior to hybridisation with the array, the nucleic acid sample is restricted with one or more restriction enzymes, preferably the same two restriction enzymes used in

generating the array, although this is not mandatory.

Also, the nucleic acid sample (or parts of it) may be amplified prior to hybridisation with the array, using any type of suitable amplification technique, preferably a PCR-based technique. As already mentioned above, conveniently AFLP  
5 may be used, preferably using the same adapters and primers as used in generating the array. This not only allows the use of known, reliable protocols, but can also reduce sample complexity, thereby improving the signal-to-noise ratio.

However, it should be understood that the array of the invention generally comprises a set of specific probes/markers bound to a carrier, so that the array can be  
10 used to probe any nucleic acid sample for the presence of a corresponding sequence. This is independant of the form which the nucleic acid sample may take (i.e. full genomic DNA, cDNA, or fragments thereof), or whether it has been amplified, and if so, by which amplification technique.

It should further be understood that, compared to fingerprinting, the use of the  
15 array no longer is, or has to be, based on detecting differences in fragment length, as sequences of interest can be detected directly. Therefore, the arrays of the invention, once prepared, are more broadly applicable than in AFLP only.

Also, although the array of the invention is primarily intended for detection and analysis, it may also be used to quantitatively prepare or isolate DNA, RNA or any  
20 fragment thereof, i.e. by releasing the hybridized sequences from the array after removal of unwanted sequences. The sequences thus obtained may then be used or analysed further, for instance to determine their sequence.

In principle, arrays of the invention can be developed for, and can be used for, any purpose for which a polymorphic marker can be used and/or identified. This  
25 includes, but is not limited to, all the uses described in the art for polymorphic markers in known DNA-fingerprinting, genotyping, profiling and DNA-identification techniques. The arrays of the invention are of course especially suited in those applications for which an AFLP-marker can be used and/or identified, including those mentioned above and in EP-A-0 534 858 and the co-pending European applications  
30 98.202.5496 and 98.202.4515.

Also, besides the applications already mentioned, a cDNA-based array of the

invention can be used for any purpose for which the use of cDNA-AFLP is envisaged, including but not limited to applications such as expression profiling, functional genomics, and gene mapping. For any of these applications, it is envisaged that - as with cDNA AFLP - a cDNA-based array may be used to determine both qualitatively as well as quantitatively - e.g. based on the strength of the hybridisation signal obtained with the array - the presence of one or more specific nucleotide sequences in a starting sample. These may include both DNA-sequences as well as RNA-sequences, including expression-dependant RNA sequences such as mRNAs.

Possible fields of use of both the genomic DNA-based as well as the cDNA-based arrays are for instance plant and animal breeding, variety or cultivar identification, diagnostic medicine, disease diagnosis in plants and animals, identification of genetically inherited diseases in humans, family relationship analysis, forensic science, organ-transplant, microbial and viral typing such as multiplex testing for strains of infectious diseases; as well as the study of genetic inheritance, gene expression, mutations, oncogenes and/or drug resistance; or for mRNA detection.

Arrays of the invention may further be developed for and used in any other application for which known nucleotide arrays are used or envisaged. These include the applications mentioned in for example WO 97/27317, WO 97/22720, WO 97/43450, EP 0 799 897, EP 0 785 280, WO 97/31256, WO 97/27317 and WO 98/08083.

As already mentioned above, in these applications, it is envisaged that arrays of the invention can be developed that carry most or even all markers of interest for a specific genotyping collection, such as for a specific species. Other arrays of the invention may contain most or all markers necessary to classify an individual within a genotyping collection, i.e. as belonging to a certain species, subspecies, variety, cultivar, race, strain or line, or to study the inheritance of a genetic trait or property. Also, an array of the invention may contain all markers indicative of the presence, the absence or the state of a genetically determined or genetically influenced disease or disorder, including cancer, oncogenes and oncogenic mutations. Such an array may then be used for diagnostic purposes.

Similarly, it may be possible to provide cDNA-based arrays for any of these purposes.

Some non-limiting examples of species of plants, animals and micro-organisms for which arrays of the invention are particularly envisaged include humans, animals such as mouse, rat, pig, etc., plants such as wheat, barley, maize, tomato, pepper, lettuce, rice, and micro-organisms such as yeast, bacteria and fungi-algi.

In a further aspect, the invention relates to results and/or data obtainable by analysing a nucleic acid or mixture of nucleic acids with an array of the invention. These results or data may for instance be in the form of an image, of a score, of digital or analog data, or in another suitable form, and may optionally be stored on a suitable data carrier, including paper, photographic film, computer disc of files, a database, etc.. This data may be as directly obtained from analysing or scoring the array, or may have been processed further.

The invention will now be further illustrated by means of the following non-limiting Experimental Part, as well as by the enclosed Figures 1-8, which show (representations of) the results of hybridisations using micro-arrays of the invention, obtained by scanning the arrays using the Genetac 1000 scanner (Genomic solutions). The arrays are irradiated with a Xenon-lamp and the signals are detected using a CCD-camera. Filters for Cy-3 and Cy-5 are used. The scantime is about 180 sec.

More specifically, the Figures show:

- Figure 1: Detection of a mixture of 5 rice +2/+3 AFLP markers on an array containing 20 rice +2/+3 AFLP markers.
- Figure 2: Detection of rice AFLP markers amplified in +2/+3 AFLP reactions on an array containing 10 rice +2/+3 AFLP markers.
- Figure 3: Detection of rice AFLP markers amplified in a +2/+2 AFLP reaction on an array containing 20 rice +2/+3 AFLP markers.
- Figure 4: Detection of a rice AFLP markers amplified in rice +2/+2 AFLP reactions on an array containing 20 rice AFLP markers.
- Figure 5: Detection of maize +2/+3 AFLP markers on an array containing 48 maize +3/+3 AFLP markers
- Figure 6: Detection of +2/+3 AFLP markers on an array containing 11 *Arabidopsis* +2/+3 AFLP markers.
- Figure 7: Detection of +2/+2 AFLP markers on an array containing 21 +1/+2

tomato cDNA-AFLP fragments.

- Figure 8: Detection of rice AFLP markers amplified in a +2/+3 AFLP reaction on an array containing 5 rice +2/+3 AFLP markers and 5 sets of oligo's corresponding to the forward and reverse strands of these 5 rice +2/+3 AFLP markers.
- Figure 9: Schematic representation of the related AFLP-Primer Combinations ("APCs") used in Example I. Fig. 9A: 4 related APCs of the Enzyme Combination ("EC") *EcoRI-MseI*; Fig. 9B: APC that can be used to simultaneously amplify the 4 APCs of Fig. 9A; Fig. 9C: 16 related APCs of the EC *PstI-TaqI*; Fig. 9D: APC that can be used to simultaneously amplify the 16 APCs of Fig. 9C.
- Figure 10: Schematic representation of the method used in generating the Array-bound Nucleic Acids Sequences ( including the AFLP-amplification);
- Figure 11: Schematic representation of the method for identifying, in/from a plurality of AFLP-fingerprints, polymorphic bands suitable for use in an array of the invention, and for "building up" an array from such polymorphic bands;
- Figure 12: Schematic representation of a method for probing a genomic DNA with an array of the invention, in which the genomic DNA is restricted and amplified using AFLP-methodology prior to contacting with the array.

## **Experimental Part.**

### **Example I: Generation of AFLP micro-arrays.**

The method for generating the AFLP micro-arrays comprises steps (1) - (9). Steps (2) - (5) generally follow conventional AFLP-techniques and protocols, as described in EP-0 534 858. A number of steps of said method, as well as the primers/primer combinations used therein, are schematically shown in Figures 9-11.

#### **1. Selection of the genotyping collection.**

A limited number of individuals is selected representing the genetic diversity within a specific group in the best possible way. The selected set of individuals is called the "genotyping collection".



The group chosen will be dependant upon the purpose of the array. For instance, when the array is to be used in breeding, the individuals may be from different varieties, lines, strains, cultivars, or races, belonging to the same species.

The number of different individuals will vary, dependant upon the nature of the genotyping collection, the diversity in said collection, the number of markers desired on the array, etc. Usually, the array will contain the markers from 1 to 10 different individuals.

## 2. Isolation of genomic DNA and preparation of AFLP template DNA.

Genomic DNA is isolated from the individuals of the genotyping collection and AFLP template DNA is prepared of each individual using a certain Restriction Enzyme Combination, as shown in Figure 10. This is carried out for each individual separately, in a manner known per se, for instance from AFLP, essentially as described in EP-0 534 858.

The Restriction Enzyme Combination will comprise at least one frequent cutter and at least one rare cutter as described above and will depend on the genotyping collection used (i.e. which genus or species).

Suitable Restriction Enzyme Combinations, i.e. providing informative polymorphic bands in the final fingerprint, can be selected on the basis of experience or after some routine experimentation. Some non-limiting examples include *EcoRI/MseI* or *PstI/TaqI*. Usually, when a Restriction Enzyme Combination is known that gives informative results in conventional AFLP-fingerprinting, this combination is also used in preparing the array of the invention.

After the genomic DNA has been isolated and restricted with the Restriction Enzyme Combination, adapters are attached to the resulting fragments to provide AFLP-template DNA. Again, conventional AFLP-adapters can be used, essentially as described in EP-0 534 858.

## 3. Amplification.

The DNA templates from each of the individuals from the genotyping collection are amplified using selective primers.

Preferably, a large number of AFLP reactions is performed on the genotyping collection using a set of "related AFLP-Primer Combinations", hereinbelow referred to as "related APCs". The APCs mentioned in this Example are also schematically shown in Figures 9A-9D.

Related APCs are combinations of selective AFLP-primers that can be used with the same Restriction Enzyme Combination and that can be amplified simultaneously using a corresponding APC with less selective nucleotides, yielding all AFLP fragments from the related APCs at once. Each of the primers that forms part of an APC is essentially the same as a conventional AFLP-primer in that it contains:

1) a sequence corresponding to (i.e. that can hybridize with) the adapter-sequence of the template, connected at its 3' end to:

2) a (usually small) sequence that corresponds to the part of the template sequence that resulted from the cutting of a restriction site in the original genomic DNA with the restriction enzyme used and the ligation of the restricted fragment to the adapter; and

3) at the 3' end of the primer, a number of so-called selective bases, for which further reference is made to EP-0 534 858.

Each primer of an APC can be represented schematically as:

5'- AAAAAAAAAAAAAA - RRR - NNN -3'

in which N is a nucleotide corresponding to the adapter sequence, R is a nucleotide corresponding to the restriction sequence, N is a selective nucleotide (the number of nucleotides A, R, and N may vary and may be different than shown); or alternatively as

[adapter] - [restr.enzyme] - NNN

in which [adapter] is the adapter sequence, [restr.enzyme] is the restriction sequence, and N is a selective nucleotide.

Each APC will consist of two primers, i.e. one primer for the rare cutter and one primer for the frequent cutter. A set of APCs will comprise a number of such two-primer APCs.

To provide a set of "related APCs", the last selective base at the 3' end of the primer for the frequent cutter, of the primer for the rare cutter, or of the primers for both, may be varied to two or more, and preferably all four of the bases A, T, G and C.

If one of the two primers of an APC is varied to all four bases, this will provide a set of 4 APCs; if both of the primers are varied, a set of 16 APCs will be obtained. Examples of such sets of related AFLP-primer combinations are:

A) a set of 4 related APCs for the Restriction Enzyme Combination *EcoRI*-*MseI* (Figure 9A):

[Adapter] - [*EcoRI*] - GAC + [Adapter] - [*MseI*] - TCA

[Adapter] - [*EcoRI*] - GAC + [Adapter] - [*MseI*] - TCC

[Adapter] - [*EcoRI*] - GAC + [Adapter] - [*MseI*] - TCG

[Adapter] - [*EcoRI*] - GAC + [Adapter] - [*MseI*] - TCT

These APCs can be used with the Restriction Enzyme Combination *EcoRI*-*MseI* and have the selective nucleotides GAC at the *EcoRI*-primer and the selective nucleotides TC at the *MseI*-primer in common. The AFLP-fragments from these 4 related APCs can be amplified at one with the APC

[Adapter] - [*EcoRI*] - GAC + [Adapter] - [*MseI*] - TC (Figure 9B)

B) the 16 related APCs for the Restriction Enzyme Combination *PstI*-*TaqI* (Figure 9C):

[Adapter] - [*PstI*] - CA + [Adapter] - [*TaqI*] - AGA

[Adapter] - [*PstI*] - CA + [Adapter] - [*TaqI*] - AGC

[Adapter] - [*PstI*] - CA + [Adapter] - [*TaqI*] - AGG

[Adapter] - [*PstI*] - CA + [Adapter] - [*TaqI*] - AGT

[Adapter] - [*PstI*] - CC + [Adapter] - [*TaqI*] - AGA

[Adapter] - [*PstI*] - CC + [Adapter] - [*TaqI*] - AGC

[Adapter] - [*PstI*] - CC + [Adapter] - [*TaqI*] - AGG

[Adapter] - [*PstI*] - CC + [Adapter] - [*TaqI*] - AGT

[Adapter] - [*PstI*] - CG + [Adapter] - [*TaqI*] - AGA

[Adapter] - [*PstI*] - CG + [Adapter] - [*TaqI*] - AGC

[Adapter] - [*PstI*] - CG + [Adapter] - [*TaqI*] - AGG

[Adapter] - [*PstI*] - CG + [Adapter] - [*TaqI*] - AGT

[Adapter] - [*PstI*] - CT + [Adapter] - [*TaqI*] - AGA

[Adapter] - [*PstI*] - CT + [Adapter] - [*TaqI*] - AGC

[Adapter] - [*Pst*I] - CT + [Adapter] - [*Taq*I] - AGG

[Adapter] - [*Pst*I] - CT + [Adapter] - [*Taq*I] - AGT

These APCs can be used with the Restriction Enzyme Combination *Pst*I-*Taq*I and have the selective nucleotide C at the *Pst*I-primer and the selective nucleotides AG at the *Taq*I-primer in common. The AFLP-fragments from these 4 related APCs can be amplified at once with the APC

[Adapter] - [*Pst*I] - C + [Adapter] - [*Taq*I] - AG (Figure 9D)

Preferably, in an APC, primers with 1, 2, 3 or 4 selective nucleotides are used. More preferably, each APC comprises a combination of two +3-primers, or one +3-primer and one +2-primer, or two +2 primers.

#### 4. Fingerprinting.

After a suitable set of related APCs has been selected, the restricted genomic DNA of an individual from the genotyping collection is amplified using one APC from the set.

This is carried out for all individuals of the genotyping collection, in separate amplifications, carried out essentially as described in EP-0 534 858, which are usually run simultaneously.

The resulting AFLP reactions, one for each individual of the genotyping collection, are then analyzed in parallel on sequencing gels. After electrophoresis, these gels are dried on Whatman 3 MM paper and the AFLP fingerprints are visualized, e.g. by autoradiography or phospho-imaging.

In this way the AFLP fingerprints of the individuals of the genotyping collection are displayed side by side on the fingerprint. This is schematically shown in Figure 11, in which the AFLP-reactions of a genotyping collection of 4 individuals (referred to "ind.1" to "ind.4" - and corresponding to the lanes from left to right in the gels) have been visualised in the four parallel lanes of each of the gels "pk 1" to "pk 4" (in which each gel was generated with a different APC from a set of four related APCs).

#### 5. Identification of polymorphic bands.

The AFLP fingerprints of the individuals of the genotyping collection are inspected for AFLP fragments that reveal DNA polymorphisms; such AFLP fragments are called "AFLP markers". This is again schematically shown in Figure 11, in which each marker has been circled. Bands that are the same for each individual fingerprint are not selected. These bands are then assembled on the array, i.e. as described hereinbelow. This method is also exemplified by the method schematically shown in Figure 12.

#### 6. Isolation of the AFLP-markers.

The AFLP markers are cut out from the gel with the gel piece and the attached Whatman 3 MM paper. This is carried out for each marker separately.

#### 7. Purification, reamplification and cloning.

The AFLP markers thus identified and separated are eluted from their respected gel pieces and separately reamplified using the AFLP primers (i.e. the APC) initially used to generate the AFLP fingerprint from which the AFLP marker is derived. Next, the AFLP markers are cloned into appropriately digested plasmid vectors according to standard procedures.

#### 8. Generating an AFLP fragment library.

The procedure of steps 6 and 7 is repeated for the various APCs of a set of related APCs.

This is again schematically shown in Figure 11, in which each of the gels pk 1 to pk 4 has been generated using one of the APCs from a set of four (and each gel contains, in each parallel lane, the fingerprint of one individual of the genotyping collection obtained with the APC used).

In this way an AFLP fragment library is build up containing AFLP markers identified using the genotyping collection.

**EXAMPLE II: Carrier attachment and formation of an array.**

The individual AFLP markers of the AFLP fragment library are attached to a carrier; many different AFLP fragments are attached to the same carrier. This is preferably carried out according to a predetermined pattern, in which for instance the markers generated from the genotyping collection with a specific APC are grouped together, i.e. as a column as shown in Figure 11.

Also, the markers generated with each of the APCs from the set of related APCs may be grouped together, to form a set of lines, rows or columns, or a rectangle, as is shown in Figure 11.

In this way an array of AFLP markers is created on the carrier. In case of a high-density array such arrays are called AFLP micro-arrays. Usually, each APC will provide about 10-50 markers, depending upon the genotyping collection and the number of individuals used.

The array thus obtained can then be used to probe the genomic DNA of a further individual for the presence of the AFLP markers attached to the array, as further described in Example III. Usually, this further individual will belong to or be related to the genotyping collection used in generating the array, or at least will be suspected of containing in its genome one or more of the markers present on the array.

**EXAMPLE III: Genotyping using AFLP micro-arrays.**

This procedure uses the AFLP micro-arrays obtained as described in Example I. Such micro-arrays contain a multitude of AFLP markers derived from a specific genus. (In general AFLP markers will be genus-specific and AFLP markers generated from a different genus will usually not be usable for genotyping of individuals from other genera).

Genotyping of a specific individual can be performed by investigating the presence or absence of each AFLP marker of the AFLP micro-array in the individual tested. This can for instance be achieved by hybridization of a collection of AFLP-fragments from the individual to the AFLP markers attached to the micro-array.

This collection of AFLP fragments is preferably generated from the individual of interest by AFLP amplification of AFLP template DNA of the individual. The

collection of AFLP fragments can be labeled to enable the detection of the AFLP fragments hybridized to their counterparts on the AFLP micro-array.

In general, this procedure comprises the following steps:

5     1. Isolation of genomic DNA and preparation of AFLP template DNA.

Genomic DNA is isolated from the individual tested and AFLP template DNA is prepared. This is carried out in a manner known per se, for instance essentially as described in EP-0 534 858.

10     Preferably, the same Restriction Enzyme Combination is used as was used in generating the template DNA for the array. More preferably, a method analogous to the method of step 2 of Example I is used, i.e. following the same or a similar protocol.

15     However, the adapters used are preferably chosen such that they do not hybridize with the adapter sequences present in the Array-bound Nucleic Acid Sequences (if any). Such hybridization between the adapter sequences could give rise to false-positive signals (i.e. not corresponding to the presence of an AFLP marker in the sample to be tested), in particular if low stringency hybridization conditions are used.

20     To avoid this, in the preparation of the template DNA to be tested with the array, different adapters to those used in generating the array may be used. Alternatively, and preferably, the adapter sequences present in the AFLP markers isolated from the gel in step 6 of Example I above are either removed or replaced by other adapter sequences prior to attachment of the marker to the array (but usually after reamplification of the isolated markers in step 7 of Example I). This may be achieved during cloning of the AFLP fragments as described in Procedure 7 of Example I.

25     2. Amplification and labelling.

A single AFLP reaction is performed on the template DNA obtained in step 1, using an APC that corresponds to the Restriction Enzyme Combination, to generate the AFLP fragments specific for the APC selected.

30     Preferably, said APC is further selected to include all APCs from the set of related APCs used to generate the markers on the AFLP micro-array, or at least a subset thereof. Generally, this means that one or both of the primers of said APC will contain

less selective nucleotides than the primers of the set of related APCs.

Usually, the primers of said APC will contain no selective bases on the positions varied in the primers of the set of "related APCs" used in generating the array, as exemplified in step 3 of Example I above. The remainder of the selective bases in primers of said APC will be the same as in the primers of the set of related APCs, also as exemplified in step 3 of Example I.

In principle, using said APC, all fragments that have been amplified separately with the set of related APCs can be amplified together. Therefore, by using said APC on the template DNA of step 1, a mixture of amplified fragments can be generated that will contain any marker generated with the set of related APCs, if such a marker is/was also present in the genomic DNA to be tested.

For the remainder, the amplification is carried out in a manner known per se, for instance essentially as described in EP-0 534 858, and preferably in a manner analogous to step 3 of Example I, i.e. following the same or a similar protocol.

During or after amplification, the AFLP fragments are labeled by using end-labeled AFLP primers, or by internal labeling. The label may be a fluorescent label, a radio-active label, or other types of labels suitable for detection on micro-arrays.

### 3. Hybridization with the array.

The labeled AFLP fragments generated with the selected APC are used as a probe in a hybridization to the AFLP fragments on the AFLP micro-array. The collection of labeled AFLP fragments is called the "AFLP target". AFLP markers represented on the AFLP micro-array will hybridize to their labeled counterparts in the AFLP target, provided that these AFLP markers are present in the individual selected. The result is that the AFLP markers on the array that correspond to markers present in the individual tested will hybridize to their labeled counterparts, and give a positive hybridization signal on the array (i.e. show the presence of the label).

AFLP markers on the array that are not present in the individual tested will not find corresponding labelled sequences in the amplified sample, and will therefore not give a positive signal.



#### 4. Scanning, detection and analysis of the array.

After hybridization, the AFLP micro-array is scanned visually or using automated equipment. Each spot harboring an AFLP marker present in the individual will show the presence of the label, spots representing AFLP markers absent in the individual will not be labeled. In this way the presence or absence of each AFLP marker on the AFLP micro-array in the individual tested can be assessed. These results may also be referenced further by comparison to earlier results obtained with the same array, or be stored in a database for future reference.

#### **EXAMPLE IV: Procedure for generating AFLP fragments for use in micro arrays.**

This method generally comprises the steps of:

1. Isolation of the fragments from an AFLP gel
2. Reamplification of the isolated fragments using primers that reconstitute the restriction sites
3. Purification and digestion of the reamplified products
4. Cloning of the fragments in pUC vector
5. Validation of the clone fragments by fingerprinting pools of cloned fragments (obtained using colony PCR), and comparing the fingerprints thus obtained with the original fingerprints used in step 1.

#### 1. Isolation of the AFLP fragments from the gel

AFLP reactions are carried out using 10 ng Mse primer and 30 ng primer for the rare cutter (of which 5 ng is kinased with  $^{33}\text{P}$   $\gamma$ -d-ATP) The AFLP reactions are run on standard 4.5% gradient gel. The gel is transferred to Whatman-3MM paper and dried. The dried gel is exposed (>0/n) with a sensitive photographic film. The fragments to be spotted on the micro array are cut out from the gel as a thin slice (about 1 mm) and transferred to 100  $\mu\text{l}$  TE<sub>0.1</sub>

## 0957498 : 01032

98L19 and 98L20, that reconstitute the restriction sites.

98L20:CGCCAGGGTTTTCCAGTCACGACGATGAGTCCTGATTAAC  
M13 forward sequence primer X  
M02: GATGAGTCCTGAGTAAC

15 The PCR reaction mixture is as follows: 5  $\mu$ l eluate; 150 ng 98L19; 150 ng 98L20; 2  $\mu$ l 5 mM dNTP's; 5  $\mu$ l 10 x PCR buffer; 0.2 U Taq polymerase, in a total volume of 50  $\mu$ l. The PCR profile is as follows: 30 sec. 94°C : 30 sec. 56°C : 1 min. 72°C. for 30 cycles.

20

30 98L89:AGCGGATAACAATTTACACAGGATAGACTGCGTACCTGC  
M13 reverse sequence primer X  
P00: GACTGCGTACATGCAG  
( 98L89 = SEQ ID no.8 ; P00 = SEQ ID no.9)

### 3. Purification and digestion of the reamplified fragments

The PCR-reactions are purified using a Qiaquick 96-well PCR centrifugation kit (Qiagen) according to the manufacturers protocol.

The elution step is carried out using 80  $\mu$ l elution buffer, to a final volume of about 50  $\mu$ l. The elution volume is collected on a microtiter plate. The purified PCR-products are restricted by adding 5U rare cutter enzyme, 5U MseI to a total volume of 74  $\mu$ l 1x RL+, and the mixture is incubated for 2 hours at 37°C. After the restriction/digestion, the DNA (on the microtiter plate) is precipitated with isopropanol by adding 7.5  $\mu$ l 3M NaOAc, 85  $\mu$ l isopropanol, and the mixture is kept at room temperature for 15 min and then centrifuged for 45 min (3500 rpm). Excess isopropanol is removed and the microtiter plates are again centrifuged (10 sec. at 1000 rpm). The pellet (not visible) is taken up in 15  $\mu$ l TE<sub>0.1</sub>, and a 3  $\mu$ l aliquot thereof is checked on the 2% agarose gel.

### 4. Cloning of the reamplified fragments

The ligation reaction is carried out in the following mixture: 7  $\mu$ l reamplification product (in PCR base); 8  $\mu$ l ligation mixture; 100 ng PstI- or EcoRI/NdeI-restricted, gel-purified pUC18; 3  $\mu$ l 5X RL<sup>+</sup>; 1.5  $\mu$ l 10 mM ATP; 1U T<sub>4</sub> DNA Ligase to a total volume of 8  $\mu$ l. The mixture is incubated (o/n) at room temperature.

The transformation (in PCR base) is carried out as follows. 7.5  $\mu$ l ligation reaction is kept on ice, 50  $\mu$ l frozen competent DH5 $\alpha$  cells are added (on ice), and the mixture is incubated for 30 min. (on ice). The mixture is then subjected to a heat shock (42°C) during 90 sec and kept on ice for 2 min, after which 200  $\mu$ l TY medium is added, and the mixture is allowed to recover (1 hour at 37°C). 200  $\mu$ l of the mixture is plated on TY+carbeniciline agar plate and incubated (o/n) at 37°C.

### 5. Reamplification and validation of the cloned fragments

The following reamplification primers are used:

- rare cutter side: 98L58: GGAAACAGCTATGACCATGATTAC (pUC 18 primer, SEQ ID no.10)
- 5 - *NdeI* side: 98L55 GATTGTACTGAGAGTGCACCTTAAC (pUC 18 primer, with reconstituted *MseI* site, only for *MseI*+, SEQ ID no.11).

For each clone fragment 3 different clones and inoculated into 10  $\mu$ l TY, followed by incubation (o/n) at 37°C. *E. coli* cells are transferred to 96-wells plate with 50  $\mu$ l TE<sub>0.1</sub> per well, and 5  $\mu$ l is transferred to PCR base. The PCR base is incubated at 95°C during 5 min, after which 45  $\mu$ l PCR mixture is added, which comprises: 75 ng primer 98L58; 75 ng primer 98L55; 2  $\mu$ l 5 mM dNTP's; 5  $\mu$ l 10X PCR buffer; 0.25  $\mu$ l Taq polymerase; 0.85  $\mu$ l 10 mg/ml BSA, to a total volume of 45  $\mu$ l. The PCR profile is as follows: 25 sec. 94°C; 30 sec. 56°C; 1 min. 72°C; for 30 cycles. 5  $\mu$ l of the mixture is checked on the gel.

15 For each APC from which a fragment is obtained, 3 pools are made. Pool A contains fragment 1, 4, 7, 10 ...; Pool B contains fragment 2, 5, 8, 11 ...; Pool C contains fragment 3, 6, 9, 12 .... For each clone 5  $\mu$ l colony PCR material is pooled, and 5  $\mu$ l of each pool is used for a template preparation (standard AFLP template).

20 The template is checked by standard AFLP reaction of 1/10 diluted pool template, the fingerprint of which is compared to the fingerprint from which the original fragments were obtained.

### **EXAMPLE V: Protocols for detecting AFLP fragments using micro arrays.**

#### Preparing the micro arrays

25 The micro arrays are prepared using DNA probes that are synthesized via "colony PCR" using pUC18 specific primers. For preparing the arrays, DNA solutions at a concentration of about 0.5  $\mu$ g/ $\mu$ l are used. Diluted colony PCR material is used for routine synthesis of probe DNA.

#### 1. Amplification of the probes

30 To synthesize as much DNA as possible in a small a volume as possible, an

adaptation of a conventional PCR protocol is used (increased amounts of primer, dNTP's and  $MgCl_2$  are added). The PCR mixture is as follows: 5  $\mu l$  1/400 preamp; 6.3  $\mu l$  primer 1 (50 ng/ $\mu l$ ); 6.3  $\mu l$  primer 2 (50 ng/ $\mu l$ ); 8.4  $\mu l$  dNTP (5 mM); 3.36  $\mu l$   $MgCl_2$  (25 mM); 10.5  $\mu l$  PCR buffer (10x); 0.525  $\mu l$  Taq DNA Polymerase (5 U/ $\mu l$ );  
5 H<sub>2</sub>O to 105  $\mu l$  final volume. The PCR profile is as follows: 30 sec. 94°C; 30 sec. 55°C; 1 min. 72°C; 30 cycles; PE 9600 MODE. The gel reference is 2.5  $\mu l$  PCR on 2% agarose gel. The following primers are used: Standard: 98L55 + 98L58; with 5'NH<sub>2</sub>: 98L59 (NH<sub>2</sub>) + 98L58 NH<sub>2</sub>; with 5' Cy-3 and internal NH<sub>2</sub>: 98L59 (Cy-3, NH<sub>2</sub>) + 98L58 (Cy-3, NH<sub>2</sub>).

10 On the basis of 315 ng of each primer, theoretically 8  $\mu g$  product can be formed in the reaction in a 105  $\mu l$  PCR (assuming an average fragment length of 250 bp and that all primer is used). For a PCR efficiency of 80%, 6.4  $\mu g$  product will be synthesized. Thus, for 50  $\mu l$  product at a concentration of about 0.5  $\mu g/\mu l$ , 3 PCR reactions of 105  $\mu l$  are necessary.

## 15 2. Precipitation of PCR reactions:

The precipitation of the PCR reactions is carried out as follows. To 3x 105  $\mu l$  PCR reaction + 31.5  $\mu l$  (1/10 volume) 3M NaAc is added 346  $\mu l$  (1 volume) 2-propanol, and the mixture is kept for 30 min at -20°C. The mixture is then  
20 centrifuged (30 min, 13000 rpm, 4°C) and the pellet is washed with 100  $\mu l$  70% EtOH. The mixture is then again centrifuged (10 min, 13000 rpm, RT) and the pellet is dried to air, dissolved in 25  $\mu l$  H<sub>2</sub>O and 25  $\mu l$  DMSO is added. As a gel reference 0.5  $\mu l$  on 2% agarose gel is used.

## 25 3. Preparation of the arrays

To prepare ("print") the arrays a GMS 417 arrayer (Genetic Microsystems) is used. Such an arrayer can be configured according to a variety of variables. In preliminary tests, a number of standard settings are used, making the lay-out of all arrays comparable. A good means for localizing the spots is the use of labelled  
30 primers -in particular Cy-3 or Cy-5-primers- for making the probes. This makes the position of the printed sequences ("spots") clearly visible on the scans of the arrays

and serves as a control to monitor deposition and binding to the array. The slides used were EMS Poly-L-lysine slides (Electron Microscopy Sciences, Washington).

Printing of the slides is carried out as follows:

a) Position of the slides:

- Piece of "matted glass" on the slides on the left side (against the clamp).
- Press slides well together.

b) Position of the microtiter plates:

- A1 coordinate of the plates left side front in the plate holders.

c) Settings arrayer:

1x spotting X = 3 Y = 15, duplo X = 7.4 Y = 15

5x spotting X = 3 Y = 19, duplo X = 7.4 Y = 19

spot spacing: 300  $\mu\text{m}$  - 350  $\mu\text{m}$ .

To limit the evaporation of the probe DNA's, the microtiter plates can be kept above a bath of warm water.

#### 4. Processing of the arrays

During the processing of the arrays, DNA is adhered to the glass carrier and denaturated, depending upon the type of slide and the coating. The processing of EMS Poly-L-lysine slides is carried out as described by P. Brown

([http://cmgm.stanford.edu/pbrown/protocols/3\\_post\\_process.html](http://cmgm.stanford.edu/pbrown/protocols/3_post_process.html));

The slide is rehydrated on top of a hot water bath for 1 minute, so that the slide becomes fogged, and snap dried on a heated cooking plate (about 3 sec.). The slide is then rehydrated for 10 sec, UV cross-linked at 65 mJ (Amersham UV crosslinker at 650 x 100  $\mu\text{J}$ ), and incubated for 15-20 min in blocking solution (in a glass tray), with gentle agitation. The blocking solution comprises 325 ml 1-methyl-2-pyrrolidone (100 ml); 6 g succinic anhydride (1.8 g) and 15 ml sodium borate (pH 8.0) (4.6 ml). The slides are washed for 2 min. in  $\text{H}_2\text{O}$  (95°C); washed for 1 min. in 96% ethanol; and dried for 5 min. by centrifugation in a tabletop centrifuge at 1000 rpm.

### 5. Labeling of the target reactions

For the labeling of the target DNA several methods can be used. Hereinbelow, a labeling method will be used in which Cy-3 or Cy-5 labelled dCTP molecules are enzymatically incorporated into the target DNA using Klenow DNA polymerase.

The PCR reaction was as follows: PCR reaction: 5  $\mu$ l 1/400 preamp or 5  $\mu$ l 1:10 AFLP template; 6.3  $\mu$ l primer 1 (50 ng/ $\mu$ l); 6.3  $\mu$ l primer 2 (50 ng/ $\mu$ l); 3.36  $\mu$ l  $MgCl_2$  (25 mM); 8.4  $\mu$ l dNTP (5 mM); 10.5  $\mu$ l Per buffer (10x); 0.525  $\mu$ l Taq DNA Polymerase (5 M/ $\mu$ l); and  $H_2O$  until 105  $\mu$ l final volume. The PCR profile is dependent upon the AFLP extension reaction. If only one selective nucleotide is used, a stable profile is used, e.g., 30 sec. 55°C; 1 min. 72°C; for 30 cycles, PE 9600 MODE. With more than one selective nucleotide, a standard AFLP profile (with touch down) is used, e.g 30 sec. 94°C; 30 sec. 65°C 1 cycle; 1 min. 72°C; followed by lowering of the annealings temp. with 0.7°C during 12 cycles (in total 13 cycles touch down); 30 sec. 95°C; 30 sec. 56°C - 23 cycles; 1 min. 72°C

The target reaction is precipitated as follows. 10  $\mu$ l (1/10 volume) 3 M NaAc is added to 100  $\mu$ l target PCR reaction. 110  $\mu$ l (1 volume) 2-propanol is added, and the mixture is kept for 30 min at -20°C. The mixture is then centrifuged (30 min at 13000 rpm and 4°C) and the pellet is washed with 100  $\mu$ l 70% EtOH, followed by centrifugation (10 min at 13000 rpm and RT). The pellet is then dried to ambient air and taken up in 10  $\mu$ l  $H_2O$ .

The preparation of labeled target DNA using Klenow DNA Polymerase was carried out as follows. To 5  $\mu$ l target DNA (about 3-6  $\mu$ g AFLP reaction) and 2.5  $\mu$ l AFLP primer (1  $\mu$ g/ $\mu$ l) is added  $H_2O$  to a total volume of 20  $\mu$ l, and the mixture is kept for 5 min. at 95°C and then cooled to room temperature. Then are added: 5  $\mu$ l dCTP with Cy-3 or Cy-5 label (0.5 mM); 1  $\mu$ l 5 mM of each of dATP, dGTP, dTTP; 5  $\mu$ l 10x T4 buffer; 2.5  $\mu$ l Klenow DNA Pol (8u/ $\mu$ l) and 16.5  $\mu$ l  $H_2O$ , and the mixture is incubated for 2 hours at 37°C

The labeled target reactions are purified using a Qiaquick column, according to the manufacturer's instructions. The elution is in 50  $\mu$ l elution buffer.

The pellet, which must be clearly stained, is dissolved in 18  $\mu$ l H<sub>2</sub>O for Klenow target or in 15  $\mu$ l H<sub>2</sub>O for Mirus target.

### 8. Hybridisation

The denaturation of labeled target is carried out by adding 1.5  $\mu$ l denaturation buffer D1 (3M NaOH), after which the mixture is kept at room temperature for 5 min, and then placed on ice, upon which 1.5  $\mu$ l neutralisation buffer N1 (1M Tris pH 7.3, 3M HCl) is added.

Subsequently, 18  $\mu$ l 2x hybridization buffer (preheated), comprising 4x SSC, 5x Denhardt, 0.5% SDS, is added at 60°C, after which the hybridization is started by, with a pipet, adding 30  $\mu$ l target solution to the slide, next to the array.

A the cover glass (24x50 mm) is placed in position (without air bubbles), and the slides are incubated (o/n) at 45°C in a single incubation chamber (in which case 2 drops 10  $\mu$ l 3x SSC are added) or in a large incubation tank containing water.

The hybridizations are washed by rinsing with 4x SSC 0.1% SDS (45°C); incubating for about 5 min in 2x SSC 0.1% SDS (45°C); incubating for 5 min 1x SSC 0.1% SDS (RT); incubating for 5 min in 0.5x SSC 0.1% SDS (RT); incubate for 2 min in 0.5x SSC (RT); followed by centrifugation for 10 min (500 rpm) in a tabletop centrifuge.

### 9. Scanning

The arrays are scanned using the Genetac 1000 scanner (Genomic solutions). The arrays are irradiated with a Xenon-lamp and the signals are detected using a CCD-camera. Filters for Cy-3 and Cy-5 are used. The scantime is about 180 sec.

### **EXAMPLE VI: Detection of AFLP markers on microarrays.**

#### EXAMPLE VI-1: Detection of a mixture of 5 rice +2/+3 AFLP markers on an array containing 20 rice +2/+3 AFLP markers.

An array of 20 rice +2/+3 AFLP markers (probes) was prepared from cloned



AFLP markers generated using restriction enzymes *EcoRI* and *MseI* and parental lines IR20 and 6383. The AFLP marker name, AFLP primer combination (PC) used, estimated mobility (size in basepairs) and the parental origin of these 20 AFLP markers are:

5

	PC	Size (b.p.)	Parent Line
	1. E11/M47	145	IR20
	2. E11/M50	342	IR20
	3. E11/M50	173	IR20
10	4. E11/M50	143	IR20
	5. E11/M50	101	IR20
	6. E11/M49	583	IR20
	7. E11/M49	243	IR20
	8. E11/M49	210	IR20
15	9. E11/M49	200	IR20
	10. E11/M49	196	IR20
	11. E11/M47	160	6383
	12. E11/M50	214	6383
	13. E11/M49	342	6383
20	14. E11/M49	299	6383
	15. E11/M49	273	6383
	16. E11/M49	247	6383
	17. E11/M49	194	6383
	18. E11/M49	159	6383
25	19. E11/M49	149	6383
	20. E11/M49	146	6383

The of sequences the +2/+3 AFLP primers used to generate these 20 AFLP markers are:

*EcoRI* E11: 5'-GACTGCGTACCAATTCAA-3' (SEQ ID no.12)  
*MseI* M47: 5'-GATGAGTCCTGAGTAACAA-3' (SEQ ID no.13)  
M49: 5'-GATGAGTCCTGAGTAACAG-3' (SEQ ID no.14)  
M50: 5'-GATGAGTCCTGAGTAACAT-3' (SEQ ID no.15)

The AFLP reactions used to isolate the 20 AFLP +2/+3 makers were generated and resolved on sequence gels using the standard procedure (Vos et al., Nucleic Acids Research 23; 4407-4414, 1995 and EP 0 534 858). The AFLP markers were excised from a sequencing gel after transfer to Whatmann paper, followed by drying and exposure to X-ray film to visualize the fingerprint pattern and reamplified using primers :

5'-AGCGGATAACAATTTACACAGGATAGACTGCGTACGAATTCA-3' (SEQ ID no.16) and  
5'-CGCCAGGGTTTTCCAGTCACGACGATGAGTCCTGATTAAAC-3' (SEQ ID no.17) as described in the protocol.

After cutting with *EcoRI* and *MseI* and purification using Qiagen PCR purification kits (Qiagen) the restricted AFLP marker fragments were cloned in plasmid vector digested with *EcoRI* and *NdeI*. After transformation to *E. coli*, recombinant clones were validated for the correct size insert by AFLP fingerprint analysis of pooled amplified clone inserts. The inserts of clones with validated inserts were sequenced using a standard dye terminator cycle sequencing kit (ABI) according to standard protocols supplied by the manufacturer.

Insert DNAs of individual validated clones were amplified from bacterial stocks by PCR using either unlabelled vector primers or Cy3-labelled vector primers as described (see protocol enclosed) and the PCR reactions were precipitated using n-propanol and sodiumbicarbonate according to standard procedures. DNAs were resuspended in 50% DMSO to a final concentration of around 500 nanograms per microliter.

Microarrays were prepared by depositing in duplo around 250 picoliters (1

time spotting) of either the unlabelled or the Cy3-labelled DNA solutions onto an EMS poly-L-lysine slide, (Electron Microscopy Sciences, Washington) using a GMS417 microarrayer (Genetic Microsystems, Woburn, MA). The slide was processed according to standard procedures (see protocol enclosed) and hybridized overnight at 45 °C temperature with a mixture of 5 AFLP markers (target) named 8, 10, 15, 17, and 19 as indicated above, after labelling with Cy5 dye (Amersham Pharmacia Biotec) by Klenow enzyme according to standard procedures (see protocol enclosed). After washing according to the protocol, the slide was scanned at the Cy3 channel for 300 seconds (Figure 1B) and at the Cy-5 channel in the automatic exposure mode ("auto"; Figure 1C) using a Genetac1000 microarray slide scanner (Genomic Solutions, Ann Arbor, MI).

The superimposed image of both channels is shown in Figure 1A with annotation to facilitate interpretation of the spotting pattern. Figure 1 shows:

- 1) uniform deposition of all AFLP probes (red, green or yellow signal of all probes on false-color image after hybridization).
- 2) specific hybridization to the 5 expected AFLP probes 8, 10, 15, 17 and 19 (Cy5 channel, green on false-color image; in combination with Cy3-labelled fragments yellow on false-color image).
- 3) no hybridization to the remaining 15 AFLP probes 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 14, 16, 18 and 20).

EXAMPLE VI-2: Detection of rice AFLP markers amplified in +2/+3 AFLP reactions on an array containing 10 rice +2/+3 AFLP markers.

An array containing 10 rice AFLP markers (probes) was prepared exactly as described in Example VI-1. The array was processed as described and hybridized with a target consisting of a mixture of a Cy5-labelled AFLP +2/+3 reaction (target) derived from parental line 6383 and IR20, prepared with AFLP primers E11 and M49. With this primer combination, parental line IR20 is known to contain AFLP markers 6, 8 and 10 and line 6383 is known to contain AFLP markers 14, 16, 18 and 20 as described in Example VI-1. The array was washed according to the conditions as described in Example VI-1 or protocols referred to in Example VI-1.

Following washing, images were taken at the Cy3 (Figure 2B) and Cy5 (Figure 2C) channels as described in Example VI-1 and the two images were superimposed electronically (Figure 2A). Figure 2 is annotated to facilitate interpretation of the spotting pattern and shows:

- 1) uniform deposition of all AFLP probes (red, green or yellow signal of all probes on false-color image after hybridization).
- 2) specific hybridization of the IR20 and 6383 AFLP markers 6, 8, 10, 14, 16, 18 and 20; Cy5, green signal on false-color image hybridized to unlabelled probes and green/yellow signal on false-color image hybridized to Cy3 labelled probes).
- 3) no hybridization of to the remaining AFLP markers 2, 4 and 12; Cy3, red signal on false-color image).

EXAMPLE VI-3. Detection of rice AFLP markers amplified in a +2/+2 AFLP reaction on an array containing 20 rice +2/+3 AFLP markers.

An array containing 20 rice AFLP markers (probes) was prepared exactly as described in Example VI-1. The array was processed as described and hybridized using a Cy5-labelled AFLP +2/+2 reaction (target) derived from parental line 6383, prepared with AFLP primers E11 and M15: 5'-GATGAGTCCTGAGTAACA-3' (SEQ ID no.18). This parental line is known to contain AFLP markers with names 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 as described in Example VI-1. The array was washed according to the conditions as described in Example VI-1 or protocols referred to in Example VI-1.

Following washing, images were taken at the Cy3 (Figure 3B) and Cy5 (Figure 3C) channels as described in EXAMPLE VI-1 and the two images were superimposed electronically (Figure 3A). The superimposed image is shown in Figure 3A with annotation to facilitate interpretation of the spotting pattern. Figure 3 shows:

- 1) uniform deposition of all AFLP probes (red, green or yellow on false-color image).
- 2) specific hybridization to the AFLP markers in positions 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 (Cy5; green signal on false-color image; in combination with Cy3

labelled AFLP probes yellow signal on false-color image)

- 3) (cross)-hybridization to the IR20 derived AFLP probes in positions 2 and 3 (Cy5; green signal on false color image), probably due to co-amplification of AFLP fragments with sequence similarity to IR20 markers in positions A2 and A3 with AFLP primer combinations E11/M15 from 6383 AFLP template.
- 4) no hybridization to remaining eight IR20-derived AFLP probes 1, 4, 5, 6, 7, 8, 9 and 10.

EXAMPLE VI-4. Detection of a rice AFLP markers amplified in rice +2/+2 AFLP reactions on an array containing 20 rice AFLP markers.

An array containing 20 rice AFLP markers (probes) was prepared exactly as described in Example VI-1. The array was processed as described and hybridized with a target consisting of a mixture of a Cy3-labelled AFLP +2/+2 reaction (target) derived from parental line IR20, prepared with AFLP primers E11 and M15, and a Cy5-labelled AFLP +2/+2 reaction derived from parental line 6383, also prepared with primer combination E11 and M15 (for primer sequences see Example VI-2). The parental line IR20 is known to contain AFLP markers 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 and 6383 is known to contain AFLP markers 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 as described in Example VI-1. The array was washed according to the conditions as described in Example VI-1 or protocols referred to in Example VI-1.

Following washing, images were taken at the Cy3 (Figure 4B) and Cy5 (Figure 4C) channels both at 180 seconds exposure time and the two images were superimposed electronically (Figure 4A). The superimposed image of both channels is shown in Figure 4A with annotation to facilitate interpretation of the spotting pattern. Figure 4 shows:

- 1) uniform deposition of all AFLP probes (red, green or yellow on false-color image after hybridization).
- 2) specific hybridization of IR20 AFLP markers 1, 4, 6, 7, 9 and 10; Cy3, red on false-color image).
- 3) specific hybridization of 6383 AFLP markers 11, 14, 15, 17 and 20; Cy5, green on false-color image).

- 4) Hybridization of both IR20 and 6383 AFLP markers 2, 3, 12, 13 and 18; yellow on false-color image).
- 5) No hybridization to probes 5, 8, 16 and 19.

5 EXAMPLE VI-5. Detection of maize +2/+3 AFLP markers on an array containing 48 maize +3/+3 AFLP markers

10 An array of 48 maize +2/+3 AFLP markers (probes) was prepared from cloned AFLP markers generated using restriction enzymes *EcoRI* and *MseI* and parental lines B73, Mo17, F2, Co255, DK105 and A7. The AFLP marker name, AFLP primer combination (PC) used, estimated mobility (size in basepairs) and the parental origin of these 48 AFLP markers are:

AFLP Marker Name	PC	Size (bp)	Parent Line
A1	E33/M50	596	Mo17
A2	E33/M50	588	Mo17,Co255
A3	E33/M50	580	B73,A7
A4	E33/M50	566	B73,Mo17,Co255,A7
A5	E33/M50	526	B73,Mo17,Co255
A6	E33/M50	503	F2,DK105
A7	E33/M50	459	DK105
A8	E33/M50	453	B73,DK105
A9	E33/M50	447	B73,Mo17,Co255,DK105,A7
A10	E33/M50	434	Mo17,F2,Co255,
A11	E33/M50	424	F2,Co255,A7
A12	E33/M50	416	B73,Mo17,F2,Co255,DK105,A7
C1	E33/M50	308	Mo17,F2,Co255
C2	E33/M50	304	B73,Mo17,F2,Co255,DK105,A7
C3	E33/M50	292	B73,Mo17,F2,DK105,A7
C4	E33/M50	290	B73,Mo17,F2,Co255,DK105,A7

C5	E33/M50	280	B73,Mo17,A7
C6	E33/M50	274	Mo17,F2,Co255,DK105
C7	E33/M50	269	DK105
C8	E33/M50	264	B73,Mo17,F2,DK105
C9	E33/M50	262	Mo17,Co255
C10	E33/M50	258	B73,A7
C11	E33/M50	255	F2
C12	E33/M50	252	B73,Mo17,Co255,DK105,A7
E1	E33/M50	205	Mo17
E2	E33/M50	204	F2
E3	E33/M50	202	B73,Mo17,A7
E4	E33/M50	201	F2
E5	E33/M50	196	B73,Co255
E6	E33/M50	181	B73,A7
E7	E33/M50	179	Mo17
E8	E33/M50	171	Dk105
E9	E33/M50	169	B73,A7
E10	E33/M50	168	F2
E11	E33/M50	167	B73,F2,A7
E12	E33/M50	161	F2
G1	E33/M50	131	Mo17
G2	E33/M50	128	F2,DK105,A7
G3	E33/M50	127	B73,Mo17,F2,Co255
G4	E33/M50	124	B73,Mo17,Co255,DK105
G5	E33/M50	121	B73
G6	E33/M50	113	Mo17,A7
G7	E33/M50	113	B73,DK105,A7
G8	E33/M50	111	A7
G9	E33/M50	109	F2,Co255
G10	E33/M50	109	Mo17,F2,Co255

G11	E33/M50	106	B73,Mo17,F2,DK105,A7
G12	E33/M50	103	B73,F2,Co255,DK105,A7

The sequences the +2/+3 AFLP primers used to generate these 48 AFLP markers are:

E33: *EcoRI*: 5' GACTGCGTACCAATTCAAG-3' (SEQ ID no.19)

5 M50: *MseI*: 5'GATGAGTCCTGAGTAACAT-3' (SEQ ID no.20)

The AFLP reactions used to isolate the 48 AFLP +3/+3 makers were generated, excised, reamplified, purified, cloned and validated as described in the protocol of Example VI-1. The inserts of clones with validated inserts were sequenced using a standard dye terminator cycle sequencing kit (ABI) according to standard protocols supplied by the manufacturer.

Insert DNAs of individual validated clones were amplified from bacterial stocks by PCR using either unlabelled vector primers or Cy3-labelled vector primers as described in Example VI-1.

PCR reactions were precipitated and dissolved as described in the protocol of Example VI-1. Microarrays were prepared by depositing in duplo around 250 picoliters (1 time spotting) or 1250 picoliters (5 times spotting) of either the unlabelled or the Cy3-labelled DNA solutions, processed and hybridized according to the protocol of Example VI-1. The target was a mixture of complete +2/+3 E33/M50 AFLP reactions of the parental lines B73 and F2, after labeling the B73 DNA with Cy5 dye (Amersham Pharmacia Biotec), and the F2 DNA with Cy3, by Klenow enzyme according to standard procedures (see protocol enclosed). After washing according to the protocol, the slide was scanned at the Cy5 and Cy3 channels for 180 seconds each using a Genetac1000 microarray slide scanner (Genomic Solutions, Ann Arbor, MI).

The superimposed image of both channels is shown in Figure 5 with annotation to facilitate interpretation of the spotting pattern. Figure 5 shows:

- 1) uniform deposition of all AFLP probes (red, green or yellow signal of all probes on false-color image after hybridization).



- 2) specific hybridization of B73 target to expected AFLP probes A3, C5, E9, E11, G7, C10, and E6 (Cy5 channel, green on false-color image);
- 3) Specific hybridisation of F2 target to expected AFLP probes A6, A8, A11, G7 and G10 (Cy3 channel, red on false-color image);
- 5 4) Specific co-hybridization of B73 and F2 targets to expected probes A12, C3, C4, C8 and G12 (Cy5 and Cy3 channels, yellow on false-color image);
- 5) Strong non-specific cross-hybridisation to probes A9, C7, G5, A8, C2, C6, C12, E8 and G8;
- 6) Weak non-specific cross-hybridisation to probes A1, E1, G1, G12, A2, A4 and A10;
- 10 7) No hybridisation to probes C1, C11, G3, E2, E4, E10, E12, G2 and G4;
- 8) Specific lack of hybridization to the AFLP probes A1, A9, E1 and G6.

EXAMPLE IV-6. Detection of +2/+3 AFLP markers on an array containing 11 arabidopsis +2/+3 AFLP markers.

Arrays of 11 Arabidopsis +2/+3 AFLP markers (probes) were prepared from cloned AFLP markers generated using restriction enzymes *EcoRI* and *MseI* and parental lines Columbia and Landsberg erecta. The AFLP marker name, AFLP primer combination (PC) used, estimated mobility (size in basepairs) and the parental origin of these 11 AFLP markers are:

AFLP marker name	PC	Size (basepairs)	
Parent Line			
1. A3	E11/M62	560	Columbia.
2. A5	E11/M62	512	Columbia.
3. A7	E11/M62	426	Landsberg er.
4. A9	E11/M62	357	Landsberg er.
5. A11	E11/M62	306	Landsberg er.
6. C1	E11/M62	274	Columbia.
7. C3	E11/M62	271	Columbia.
8. C5	E11/M62	207	Landsberg er.

9. C7	E11/M62	171	Columbia.
10. C9	E11/M62	163	Columbia.
11. C11	E11/M62	153	Columbia.

5           The sequences of the +2/+3 AFLP primers used to generate these 11 AFLP markers are:

E11: *EcoRI*: 5'-GACTGCGTACCAATTCAA-3' (SEQ ID no.21)

M62: *MseI*: 5'-GATGAGTCCTGAGTAACTT-3' (SEQ ID no.22)

10           The method used to generate the 11 AFLP +2/+3 markers and the preparation and processing of the arrays containing these 11 *Arabidopsis* AFLP markers is as described in Example VI-1 or protocols referred to in Example VI-1.

15           The arrays were hybridized with targets consisting of a Cy5-labelled AFLP +2/+3 reaction derived Colombia or *Landsberg erecta*, which were prepared as described in Example I. The AFLP used to generate the labelled target were E11: 5'-GACTGCGTACCAATTCAA-3' (SEQ ID no.23 ) and M62: 5'-GATGAGTCCTGAGTAACTT-3' (SEQ ID no.24). With this primer combination, the parental line Columbia is known to contain the AFLP markers A3, A5, C1, C3, C7, C9 and C11 and parental line *Landsberg erecta* is known to contain the AFLP markers A7, A9, A11 and C5.

20           The array was washed according to the conditions described in Example VI-1 or protocols referred to in Example VI-1. Following washing, images of the array were taken at the Cy3 and Cy5 channels with a 180 second exposure time for both channels and the images were superimposed, as described in Example VI-1 (Figure 6). Figure 6A shows:

- 25           1) Specific hybridization of the Columbia AFLP markers A3, A5, C1, C3, C7, C9 and C11 (green signals on false-color image).  
2) An anonymous Cy3-labeled AFLP fragment at position A1 which marks the start position of the array (red signal on false-color image)

Figure 6B shows:

- 30           1) Specific hybridization of the *Landsberg erecta* AFLP markers A7, A9, A11 and C5, (green signal on false-color image).

- 2) An anonymous Cy3-labeled AFLP fragment at position A1 which marks the start position of the array (red signal on false-color image).

EXAMPLE VI-7. Detection of +2/+2 AFLP markers on an array containing 21 +1/+2 tomato cDNA-AFLP fragments.

Arrays of 21 tomato +1/+2 cDNA fragments (probes) were prepared from cloned cDNA-AFLP fragments using restriction enzymes *EcoRI* en *MseI* and tomato line 52201.

cDNA-AFLP reactions were carried out as described (Vos et al. Nucleic Acids Research 23: 4407-4414 and European Patent Application EP 0534858).

Line	AFLP marker name	PC	Size (basepairs)	Parent
1.	B1	E01/M16	357	52201
2.	B3	E01/M16	346	52201
3.	B5	E01/M16	336	52201
4.	B7	E01/M16	301	52201
5.	B9	E01/M16	284	52201
6.	B11	E01/M16	267	52201
7.	D1	E01/M16	175	52201
8.	D3	E01/M16	159	52201
9.	D5	E01/M16	136	52201
10.	D7	E01/M16	128	52201
11.	D9	E01/M16	122	52201
12.	D11	E01/M16	110	52201
13.	F3	E01/M17	310	52201
14.	F5	E01/M17	264	52201
15.	F7	E01/M17	259	52201
16.	F9	E01/M17	238	52201
17.	F11	E01/M17	208	52201
18.	H3	E01/M17	139	52201

19.	H5	E01/M17	131	52201
20.	H9	E01/M17	114	52201
21.	H11	E01/M17	103	52201

5 The sequences of the +1/+2 AFLP primers used to generate these cDNA-AFLP fragments are:

*Eco*RI: E01: 5'-GACTGCGTACCAATTCA-3' (SEQ ID no. 25)

*Mse*I: M16: 5'-GATGAGTCCTGAGTAACC-3' (SEQ ID no.26)

*Mse*I: M17: 5'-GATGAGTCCTGAGTAACG-3' (SEQ ID no.27)

10 The cDNA-AFLP reactions used to isolate the 21 +1/+2 fragments were generated and resolved on sequence gels using the standard procedure. Arrays were prepared according to the procedures described in EXAMPLE VI-1. cDNA-AFLP fragments were spotted in duplo as described in Example VI-1.

15 The slides were processed according to standard procedures (see protocol enclosed) and hybridised overnight at 45°C temperature with Cy3-labeled +2/+3 AFLP reactions (targets) of the following six tomato lines:

1. *Lycopersicon Esculentum* (L. esc.) accession Moneyberg
2. *L. Peruvianum* accession LA1708
- 20 3. *L. Hirsutum* G1209
4. *L. Chmielevski* LA1848
5. *L. Pimpinellifolium* LA722
6. *L. Pennelli* LA716

25 The sequences of the AFLP primers involved are E12 (5'-GACTGCGTACCAATTAC-3', SEQ ID no. 28) and M16 (sequence given above, SEQ ID no.26). Labelling with Cy3 dye (Amersham Pharmacia Biotec) by Klenow enzyme was carried out according to standard procedures as described in Example VI-1. After washing according to the protocol, the slides were scanned at the Cy3  
30 channel in the automatic exposure mode using a Genetac1000 microarray slide scanner. The images of all six hybridisations are shown in Figure 7 (A-F) with

annotation to facilitate interpretation of the spotting pattern. Figure 7 shows:

- 1) Hybridisation of all lines with cDNA-AFLP probes B5 and B11.
- 2) Hybridisation of *L. esc.* Moneyberg, *L. Hirsutum*, *L. Pimpinellifolium*, *L. Pennelli* with cDNA-AFLP probe D7 (circled).
- 3) No hybridisation of *L. Peruvianum*, *L. Chmielewski* with cDNA-AFLP probe D7.
- 4) Signal of Cy3-labelled anonymous cDNA-AFLP fragments deposited at positions B1 and H11 to serve as a marker for the position of the array on the slide.

**EXAMPLE VI-8: Detection of rice AFLP markers amplified in a +2/+3 AFLP reaction on an array containing 5 rice +2/+3 AFLP markers and 5 sets of oligo's corresponding to these 5 rice +2/+3 AFLP markers.**

An array containing 5 rice AFLP markers (probes) labeled with Cy3 and 5 sets of oligo's corresponding to these AFLP markers was prepared as described in Example VI-1 using 5 of the AFLP markers as described in Example VI-1. The oligo sets, consisting of 2 complementary oligo's, corresponding to these AFLP markers are stated below.

AFLP markernumber	Forward oligo name	Reverse oligo name
2	99f03	99f04
4	99f07	99f08
6	99f11	99f12
8	99f69	99f70
10	99f19	99f20

Oligoname	Oligo sequence
99f03	5'-GTCCTCATCAAGTAATAGTCAG-3' (SEQ ID no.29)
99f04	5'-CTGACTATTACTTGATGAGGAC-3' (SEQ ID no.30)
99f07	5'-CTTGATCAGGAAGACTTTACTC-3' (SEQ ID no.31)
99f08	5'-GAGTAAAGTCTTCCTGATCAAG-3' (SEQ ID no.32)
99f11	5'-CTTCATTTATCCTCGATACATG-3' (SEQ ID no.33)
99f12	5'-CATGTATCGAGGATAAATGAAG-3' (SEQ ID no.34)

99f69	5'-GGCAATGCAAGTAGATACTTC-3'	(SEQ ID no.35)
99f70	5'-GAAGTATCTACTTGCAATGCC-3'	(SEQ ID no.36)
99f19	5'-CAGTGTGCTAGTTGATTCCAG-3'	(SEQ ID no.37)
99f20	5'-CTGGAATCAACTAGCACACTG-3'	(SEQ ID no.38)

5

The array was processed as described and hybridized with a target, consisting of a mixture of equal volumes of Cy5-labelled AFLP +2/+3 reactions (target) derived from the parental lines IR20 and 6383, prepared with AFLP primers E11 and M49. Thus in the labeled target one of the strands of the AFLP +2/+3 reaction fragments is labeled with Cy5. The mixture of parental lines IR20 and 6383 is known to contain AFLP markers 6, 8 and 10 as described in Example VI-1. The array was washed according to the conditions as described in Example VI-1 or protocols referred to in Example VI-1.

Following washing, images were taken at the Cy3 (Figure 8B) and Cy5 (Figure 8C) channels both at 180 seconds exposure time and the two images were superimposed electronically (Figure 8A). The superimposed image of both channels is shown in Figure 8A with annotation to facilitate interpretation of the spotting pattern. Figure 8 shows:

- 1) uniform deposition of all AFLP probes (red, green or yellow on false-color image after hybridization).
- 2) specific hybridization to AFLP markers 6, 8 and 10; Cy5, green on false-color image).
- 3) specific hybridization to reverse sequence oligo's corresponding to the unlabeled strand of the AFLP markers 6, 8 and 10; Cy5, green on false-color image).
- 4) No hybridisation to the forward sequence oligo's corresponding to the labeled strand of the AFLP markers 6, 8 and 10.
- 5) No hybridization to AFLP markers or oligo's corresponding to AFLP markers 2 and 4.

00357468-001000

## C L A I M S

1. Array for analysing a nucleic acid sequence or mixture of nucleic acid sequences, comprising:

- 5 a) a carrier; and
- b) at least two different nucleic acid sequences bound to said carrier, in which each of the nucleic acid sequences bound to the carrier comprises at least a nucleic acid sequence that corresponds to the sequence of a restriction fragment obtainable by restricting a genomic DNA and/or at least one
- 10 cDNA with at least one frequent cutter restriction enzyme and at least one rare cutter restriction enzyme.

2. Array according to claim 1, which comprises at least 10, preferably at least 100, more preferably at least 1000 different nucleic acid sequences bound to the carrier.

15

3. Array according to claim 1 or 2, in which each of the different nucleic acid sequences is bound to the carrier in such a way that it is attached to, and corresponds with, a distinct part of the carrier, so as to form an independently detectable area of the array.

20

4. Array according to any of the preceding claims, in which the density of the different nucleic acid sequences bound to the carrier is in the range of 1-100,000 different sequences/cm<sup>2</sup>, preferably 5-10,000 different sequences/cm<sup>2</sup>, more preferably between 10-1000 different sequences/cm<sup>2</sup>.

25

5. Array according to any of the preceding claims, in which restriction fragment sequences present in the nucleic acid sequences bound to the carrier have a size of 10 to 1200 nucleotides, and may include partial nucleotide sequences obtained by restricting the restriction fragments generated from the starting genomic DNA and/or cDNA with one or more further restriction enzymes, and/or *de novo* synthesized oligonucleotides based thereon and/or derived thereof.

30

6. Array according to any of the preceding claims, in which the restriction fragments have been derived from genomic DNA, and in which at least 50%, preferably at least 70%, more preferably at least 90%, of the nucleic acid sequences bound to the carrier comprise the sequence of a restriction fragment that corresponds to an AFLP-marker.

7. Array according to claim 6, comprising a plurality of AFLP-markers taken from a single individual or from a group of related individuals.

8. Array according to claim 6 or 7, comprising several sets of AFLP-markers, in which each set comprises one or more markers taken from a single individual, wherein said sets of one or more markers have been taken from individuals belonging to a group of related individuals.

9. Array according to any of claims 6-8, in which the AFLP-markers have been taken from individuals belonging to the same species of plant, animal or micro-organism.

10. Array according to any of claims 7-9, in which the AFLP-markers have been taken from, or are representative for, different subspecies, varieties, cultivars or races of the same species.

11. Array according to claim 9 or 10, in which the AFLP-markers have been taken from plants including but not limited to wheat, barley, maize, tomato, pepper, lettuce or rice.

12. Array according to any of claims 6-9, in which the AFLP-markers have been taken from the human genome.

13. Array according to any of claims 1-12, and in particular according to claim



12, in which the AFLP-markers are representative for the presence, the absence or the state of a genetically determined or influenced disease.

14. Array according to any of claims 1-5, in which the restriction fragments have been generated from one or more cDNAs.

15. Method for providing an array of nucleic acid sequences bound to a carrier, in particular an array according to any of the preceding claims, comprising the steps of:

- a) identifying an AFLP-marker;
- b) providing a nucleic acid sequence that comprises a restriction fragment sequence corresponding to said AFLP-marker;
- c) attaching the nucleic acid sequence to the carrier; and
- d) repeating steps a) to c) for different AFLP markers to build up an array.

16. Method according to claim 15, comprising the steps of:

- a) identifying a polymorphic band in an AFLP-fingerprint;
- b) isolating a nucleic acid sequence from said polymorphic band;
- c) optionally further amplifying, purifying and/or modifying the nucleic acid sequence; and
- d) attaching the nucleic acid sequence to the carrier.
- e) repeating steps a) to d) for different polymorphic bands to build up an array.

17. Method for providing an array of nucleic acid sequences bound to a carrier, in particular an array according to any of the preceding claims, comprising the steps of:

- a) providing a nucleic acid sequence that comprises at least one restriction fragment that has been derived from at least one cDNA.
- b) attaching the nucleic acid sequence to the carrier; and
- c) repeating steps a) and b) for different cDNA-derived restriction fragments to build up an array.

18. Method according to claim 17, comprising the steps of:

- 5
- a) analysing at least one cDNA using AFLP-methodology to provide a cDNA-AFLP fingerprint, said fingerprint comprising at least one, and usually a plurality, of bands;
  - b) isolating from at least one of said bands at least one nucleic acid sequence;
  - c) optionally further amplifying, purifying and/or modifying the nucleic acid sequence;
  - d) attaching the nucleic acid sequence to the carrier; and
  - 10 e) repeating steps a) to d) for different bands and/or for different cDNAs to build up an array.

19. Array, obtainable by the method of any of claims 15-18.

15 20. Method for analysing a nucleic acid sequence or a mixture of nucleic acids sequences, comprising contacting said nucleic acid or mixture under hybridizing conditions with an array according to any of claims 1-14 or 19 or obtained according to the method of any of claims 15-18.

20 21. Method according to claim 20, in which the nucleic acid sequence or mixture is suspected to comprise at least one sequence that corresponds to a restriction fragment sequence present in the nucleic acid sequences present in the array, more specifically to an AFLP-marker present in the array.

25 22. Method according to claim 20 or 21, in which the nucleic acid sequence or mixture comprises DNA, in particular genomic DNA or a mixture of restriction fragments derived from genomic DNA.

30 23. Method according to any of claims 20-22, in which the nucleic acid sequence or mixture comprises a mixture of restriction fragments obtained by restricting a genomic DNA with the same frequent cutter restriction enzyme and rare cutter

restriction enzyme as used in generating the restriction fragment sequences present in the array.

24. Method according to any of claims 20-23, in which the mixture of restriction fragments contacted with the array has been amplified prior to hybridisation with the array.

25. Method according to claim 23 or 24, in which the mixture of restriction fragments has been amplified using AFLP, preferably using the same (selective) primers as used in generating the restriction fragments sequences present in the array.

26. Method according to any of claims 20-25, preferably using an array according to any of claims 6-13, in which the nucleic acid sequence or mixture of nucleic acid sequences contacted with the array has been derived from an individual related to the individual(s) from which the AFLP-markers present in the array have been taken.

27. Method according to claim 26, in which the individual from whom the nucleic acid sequence or mixture of nucleic acid sequences has been derived belongs to the same species as the individual(s) from which the AFLP-marker(s) present in the array have been taken.

28. Method according to claim 27, in which an array according to claim 11 is used to analyse a nucleic acid sequence or mixture of nucleic acid sequences derived from plants including but not limited to wheat, barley, maize, tomato, pepper, lettuce or rice.

29. Kit of parts comprising an array according to any of claims 1-14 or 19, and optionally other components for use with the array, such as restriction enzymes, polymerase(s), adapters, primers, buffers, nucleotides, labels or other detection agents, containers/packaging and manuals.

30. Non-processed or processed results or data obtainable by analysing a nucleic acid or mixture of nucleic acids with an array according to any of claims 1-14 or 19, or by a method according to any of claims 20-28, for instance in the form of an image, of a score, of digital or analog data, optionally stored on a suitable data carrier, including paper, photographic film, computer disc or files, or as a database.

5

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199

Fig 1a



Fig 1b





Fig 1c



2/10

Fig 2a




Fig 2b




Fig 2c




Fig 5

B73 and F2+2+3 AFLP DNA's hybridized to 48 maize parental E33/M50 AFLP fragments

PIN 1

PIN 2





Fig 6a

Colombia




Fig 6b

Landsberg erecta










Fig 7a




Fig 7b




Fig 7c



Fig 7d




Fig 7e






Fig 7f




6/10

**Fig 8a**

(Cy-3+Cy-5 signal)

**Fig 8b**

(Cy-3 signal)

**Fig 8c**

(Cy-5 signal)



7/10

## Fig 9a

4 related APC's of the EC *EcoRI*-*MseI*

██████████ - <i>EcoRI</i> -GAC	+	██████████ - <i>MseI</i> -TCA
██████████ - <i>EcoRI</i> -GAC	+	██████████ - <i>MseI</i> -TCC
██████████ - <i>EcoRI</i> -GAC	+	██████████ - <i>MseI</i> -TCG
██████████ - <i>EcoRI</i> -GAC	+	██████████ - <i>MseI</i> -TCT

## Fig 9b

Simultaneous amplification with

██████████ - <i>EcoRI</i> -GAC	+	██████████ - <i>MseI</i> -TC
--------------------------------	---	------------------------------

## Fig 9c

16 related APC's of the EC *PstI*-*TaqI*


██████████ - <i>PstI</i> -CA	+	██████████ - <i>TaqI</i> -AGA
██████████ - <i>PstI</i> -CA	+	██████████ - <i>TaqI</i> -AGC
██████████ - <i>PstI</i> -CA	+	██████████ - <i>TaqI</i> -AGG
██████████ - <i>PstI</i> -CA	+	██████████ - <i>TaqI</i> -AGT
██████████ - <i>PstI</i> -CC	+	██████████ - <i>TaqI</i> -AGA
██████████ - <i>PstI</i> -CC	+	██████████ - <i>TaqI</i> -AGC
██████████ - <i>PstI</i> -CC	+	██████████ - <i>TaqI</i> -AGG
██████████ - <i>PstI</i> -CC	+	██████████ - <i>TaqI</i> -AGT
██████████ - <i>PstI</i> -CG	+	██████████ - <i>TaqI</i> -AGA
██████████ - <i>PstI</i> -CG	+	██████████ - <i>TaqI</i> -AGC
██████████ - <i>PstI</i> -CG	+	██████████ - <i>TaqI</i> -AGG
██████████ - <i>PstI</i> -CG	+	██████████ - <i>TaqI</i> -AGT
██████████ - <i>PstI</i> -CT	+	██████████ - <i>TaqI</i> -AGA
██████████ - <i>PstI</i> -CT	+	██████████ - <i>TaqI</i> -AGC
██████████ - <i>PstI</i> -CT	+	██████████ - <i>TaqI</i> -AGG
██████████ - <i>PstI</i> -CT	+	██████████ - <i>TaqI</i> -AGT

## Fig 9d

Simultaneous amplification with


██████████ - <i>PstI</i> -C	+	██████████ - <i>TaqI</i> -AG
-----------------------------	---	------------------------------

8/10

**Fig 10***preparation of AFLP template-DNA*


9/10

Fig 11



10/10

Fig 12



# COMBINED DECLARATION AND POWER OF ATTORNEY #6

(ORIGINAL DESIGN, NATIONAL STAGE OF PCT OR CIP APPLICATION)

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## Array and method for analysing nucleic acid sequences

the specification of which: (complete (a), (b) or (c) for type of application)

### REGULAR OR DESIGN APPLICATION

- a. ☐ is attached hereto.  
b. ☐ was filed on \_\_\_\_\_ as Application  
Serial No. \_\_\_\_\_ and was amended on \_\_\_\_\_  
(if applicable)

### PCT FILED APPLICATION ENTERING NATIONAL STAGE

- c. ☒ was described and claimed in International application No. \_\_\_\_\_  
PCT/NL99/00743 filed on 3 December 1999  
and as amended on \_\_\_\_\_ (if any)

### ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, paragraph 1.56(a).

In compliance with this duty there is attached an information disclosure statement 37 CFR 1.97

### PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code paragraph 119 of any foreign application (s) for patent of inventor's certificate listed below and have also identified below any foreign application for patent of inventor's certificate having a filing date before that of the application on which priority is claimed.

(complete (d) or (e))

- d. ☐ no such applications have been filed  
e. ☒ such applications have been filed as follows

**EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION**

Country	Application Number	Date of filing (day, month, year)	Date of Issue (day, month, year)	Priority claimed
Europe	98204114.7	4 December 1998		Yes

**ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION**

**CONTINUATION-IN-PART**

(Complete this part only if this is a continuation-in-part application)

I hereby declare claim the benefit under Title 35, United States code, paragraph 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claim of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, paragraph 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, paragraph 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) (Filing date) (Status) (patented, pending, abandoned)

(Application Serial No.) (Filing date) (Status) (patented, pending, abandoned)

**POWER OF ATTORNEY**

I hereby appoint the following attorneys, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SHERIDAN NEIMARK, REG. NO. 29,510 ROGER L. BROWDY, REG. NO. 25,618 ANNE M. KORNBAU, REG. NO. 25,884  
NORMAN J. LATKER, REG. NO. 19,963 IVER P. COOPER, REG. NO. 28,005 ALLEN C. YUN,\* REG. NO. 37,971  
JAY M. FINKELSTEIN, REG. NO. 21,082 \*PATENT AGENT

ADDRESS ALL CORRESPONDENCE TO  
BROWDY AND NEIMARK, P.L.L.C.  
624 Ninth Street, N.W.  
Washington, D.C. 20001-5303

DIRECT ALL TELEPHONE CALLS TO:  
BROWDY AND NEIMARK, P.L.L.C.  
(202) 628-5197  
Customer Number 001444



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Full name of sole inventor: VOS, Petrus Antonius Josephina

Inventor's signature



Date 17 July 2001


Country of Citizenship: The Netherlands

Residence: RENSWOUDE, The Netherlands *NLL*

Post Office Address: Dorpsstraat 22, NL-3927 BD RENSWOUDE, The Netherlands

2-00 Full name of second inventor: VAN EIJK, Michael Josephus Theresia

Inventor's signature



Date 17 July 2001

Country of Citizenship: The Netherlands

Residence: UTRECHT, The Netherlands *NLL*

Post Office Address: Tolsteegplantsoen 43, NL-3523 AN UTRECHT, The Netherlands

3-00 Full name of third inventor: HOGERS, René Cornelis Josephus

Inventor's signature



Date 17 July 2001

Country of Citizenship: The Netherlands

Residence: EDE, The Netherlands *NLL*

Post Office Address: Aalbeek 38, NL-6715 GR EDE, The Netherlands

4-00 Full name of fourth inventor: HEIJNEN, Leo

Inventor's signature



Date 17 July 2001

Country of Citizenship: The Netherlands

Residence: VIANEN, The Netherlands *NLL*

Post Office Address: Kerkstraat 30 A, NL-4132 BE VIANEN, The Netherlands

CHECK PROPER BOX(ES) FOR ANY ADDED PAGE(S) FORMING A PART OF THIS DECLARATION